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ABSTRACT 
Neuroblastoma is the most common extracranial solid tumor in childhood, 
ranking third in prevalence among infant cancers. Despite intensive therapy with 
surgery, radiation and chemotherapy, there is a high chance of tumor recurrence. These 
children are therefore given retinoids in the maintenance phase to differentiate the 
tumor cells and to avoid/lessen this incidence. Although 13-cis retinoic acid (13-cis RA) 
is currently used to treat neuroblastoma, there is much evidence supporting the 
prevalence of its metabolite, all-trans retinoic acid (ATRA), to be the main signaling 
retinoid in vivo. 
The SK-N-SH neuroblastoma cell line, which is composed of three sub-types: 
sympatheoadrenal neuroblasts (N-type), substrate-adherent non-neuronal (S-type), and 
intermediate (I-type), was used as a model for ATRA-mediated differentiation. Through 
our research, we propose that redox status (i.e. balance of reactive oxygen species 
(ROS) and antioxidants) plays an important role in the process of neuroblastoma 
differentiation. More specifically, we first investigated the effects of supplementing 
ATRA treatment with a known, clinically relevant antioxidant, N-acetyl-L-cysteine (NAC). 
As opposed to findings in many other neuronal models, we are the first to demonstrate 
NAC enhancement of ATRA-mediated differentiation. Furthermore, our results suggest 
that NAC prevents oxidation of either ATRA, or of the nuclear environment in which 
ATRA binds to retinoic acid receptor (RAR) to induce expression of genes involved in 
neuronal differentiation. In this work, we also demonstrate that ATRA stimulates 
superoxide (O2
•) generation, which validates its induction of manganese superoxide 
dismutase (MnSOD; O2
• scavenger) in this cell model (previously published).  
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Our subsequent studies investigate the role of MnSOD in ATRA-mediated 
differentiation. Interestingly, ATRA upregulated neuronal differentiation markers 
(neurofilament M: NF-M and N-methyl-D-aspartate receptor 1: NMDAR1) (48 hrs) prior 
to induction of MnSOD (72 hrs), which might suggest that this antioxidant is not 
essential to initiate the differentiation process. Nonetheless, by reducing MnSOD activity 
(at 48 hrs), we demonstrate enhanced NF-M expression either in the absence or 
presence of ATRA. Therefore, it is apparent that basal MnSOD activity influences at 
least one marker of differentiation. Subsequent analysis at 96 hrs demonstrates that by 
reducing MnSOD activity, there is a concomitant decrease in NF-M expression. 
Therefore, it is possible ATRA-induction of MnSOD promotes expression of at least one 
differentiation marker (neurofilament M: NF-M) at this later time point. Furthermore, we 
provide evidence for the prevalence of MnSOD-generated hydrogen peroxide (H2O2) at 
96 hrs, which may play a role in differentiation of the SK-N-SH cells.  
Our findings show enhanced NF-M expression by either supplementation with an 
exogenous antioxidant (NAC) or reduction of an endogenous antioxidant (MnSOD). We 
propose ways in which each of these can be accomplished and provide insight into the 
redox regulation of neuroblastoma differentiation. Additionally, our work provides a 
close examination of ROS and antioxidants as they are altered in this process. Because 
retinoid therapy is often met with unfavorable chemoresistance, there is a need to 
establish improved therapeutic methods, which may revolve around alteration of redox 
status.
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CHAPTER 1: INTRODUCTION 
 
NEUROBLASTOMA 
EPIDEMIOLOGY, CHARACTERIZATION 
Neuroblastoma is the most common extracranial solid tumor in childhood, 
representing approximately 7-10% of all pediatric cancers (Brodeur and Castleberry 
1993). After acute leukemia and central nervous system tumors, it is the third most 
common of all cancers in infants (American 2010). The incidence of neuroblastoma in 
the U.S. is approximately 650 new cases each year. Median age of diagnosis is less 
than 2 years of age and only about 2% of cases are found in people over the age of 10, 
including some adults (London, Boni et al. 2005) (Children’s Neuroblastoma Cancer 
Foundation). Early symptoms of childhood cancers are often non-specific and not easily 
discovered by caregivers. Thus, unfortunately, 70% of neuroblastoma cases are not 
diagnosed until after tumors have already metastasized to distant sites, including bone 
marrow (Airoldi, Cocco et al. 2008), liver (Kushner, Kramer et al. 2006), and skin (van 
Erp 1968). Widespread multifocal lesions found in the latter three organs and 
appearance on only one side of the body represent a special form of the disease called 
“4S” (D'Angio, Evans et al. 1971) . This stage is associated with a high rate of 
spontaneous maturation and subsequent survival rates of 70-90% (Levitt, Platt et al. 
2004).  
Neuroblastoma is thought to originate from developing and uncommitted neural 
crest precursor cells (Maris 2010) and is most commonly located in the adrenal medulla 
(30%) or along the sympathetic ganglia (30-35%). Other less common sites of primary 
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tumor include the pelvis (2-3%) and the neck (1-3%) (Papaioannou and McHugh 2005). 
Intra-abdominal neuroblastomas occurring on the adrenal medulla will often present 
with characteristic swelling in this area. Metastasis to the bone can cause bone pain as 
well as sudden changes in activity levels. Painless bluish subcutaneous nodules, which 
are characteristic of stage 4S disease (Ishola and Chung 2007), can also arise in 
infants. Neuroblastoma is a very unique and unpredictable cancer because tumors can 
spontaneously regress or mature into a benign ganglioneuroma, the former being most 
prevalent (Adzick and Nance 2000). In fact, neuroblastoma is considered to exhibit one 
of the highest incidences of spontaneous and complete regression of all human cancers 
(Carlsen 1990; Yamamoto, Hanada et al. 1998).  
CLASSIFICATION AND STAGING 
The International Neuroblastoma Staging System (INSS) was developed in 1986 
in order to establish a common means to classify neuroblastoma patients and their 
response to therapy (Brodeur, Seeger et al. 1988). Since its revision just two years 
later, this classification system had been used all around the world (Table 1.1) (Brodeur, 
Pritchard et al. 1993). However, because of several difficulties, the International 
Neuroblastoma Risk Group (INRG) has since developed a complementary classification 
system (Table 1.2) (Monclair, Brodeur et al. 2009). In particular the INSS means of 
staging was based on degree of surgical resection which meant that the same tumor 
could be identified as stage 1 or 3 dependent on how well the tumor was excised; which 
did not allow proper direct comparison of clinical trials. Furthermore, the INSS 
assessment of lymph node involvement was necessary; however, sampling from this 
region by any individual surgeon can vary greatly. Essentially, the INRG task force has 
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developed a new staging system that is based on tumor imaging as opposed to extent 
of surgical resection. Taken together, a staging system that is based on diagnostic 
images prior to surgery is expected to be more robust and reproducible than one that is 
based on a surgical approach bound by many limitations. 
Although the INRG staging system (INRGSS) can be employed independently, it 
is to be used in conjunction with the INRG. It is important to note that the INRGSS is not 
a substitute for the INSS, and that most cooperative groups will continue to use INSS in 
parallel with INRGSS (Monclair, Brodeur et al. 2009).    
Table 1.2: INTERNATIONAL NEUROBLASTOMA RISK GROUP STAGING SYSTEM (INRGSS)   
Table 1.1: INTERNATIONAL NEUROBLASTOMA STAGING SYSTEM (INSS) 
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SYMPTOMS, RISK ASSESSMENT, AND PROGNOSIS 
Because neuroblastoma tumors are most often found within the abdomen, 
children can present with an unusual lump or mass in this area, which may also cause 
swelling. Children may also experience much discomfort or pain in their abdomen and 
complain of being full. Masses can be found in the neck or behind the eye, causing 
protrusion. Bone metastasis is a frequent occurrence; therefore, the child may 
experience difficulty in walking. Metastasis to the backbone can lead to compression of 
the spinal cord, causing weakness, paralysis, or numbness. Tumor cells develop from 
the sympathetic nervous system and can release hormones (i.e. epinephrine and other 
catecholamines). Consequently, other, although less common, symptoms associated 
with neuroblastoma are fever, diarrhea, high blood pressure, rapid heartbeat, flushing of 
the skin, and sweating (Dome, Rodriguez-Galindo et al. 2008).  Compression of nerves 
by tumor masses can also lead to the inability to move their extremities. Several blue or 
purple spots arising on the skin can be indicative of metastasis. If the bone marrow is 
affected, the child may experience a shortage of blood cells (erythrocytes, leukocytes or 
platelets), which can result in weakness or recurrent infections (American 2011).  
 Risk-assessment of patients with neuroblastoma was developed by the 
Children’s Oncology Group (COG) in North America and is based on INSS stage and 
tumor biology. Relevant biological factors that are assessed on individual patients 
include age of diagnosis, MYCN status, histopathological characterization, and tumor 
DNA index (DNA ploidy/ copy number). Risk-based neuroblastoma treatment was 
developed that assigned patients into either low-, intermediate, or high-risk groups 
based on the above factors. Patients with low-risk neuroblastoma have a very high cure 
rate of 90% or higher (Matthay, Perez et al. 1998; Perez, Matthay et al. 2000). Studies 
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done by the COG (COG-P9641 and COG-A3961; sponsored by the National Cancer 
Institute (NCI)) in recent years have demonstrated event-free overall survival rates of 
intermediate-risk patients to be 88% and 96% respectively. The effect of age at 
diagnosis plays a very important role. Five-year survival rates for children diagnosed at 
less than one year of age are 90%. Subsequent survival rates of children diagnosed 
later are from one to four years 68%, five to nine years 52%, and ten to fourteen years 
66%. Despite intensive therapy, children placed in high-risk groups have a much lower 
long-term survival rate of 30%. Therefore, there is much research dedicated to finding 
therapies for those children with high-risk neuroblastoma. 
PROGNOSTIC MARKERS AND DIAGNOSIS 
Prognostic markers of neuroblastoma can be divided into various subsets such 
as DNA or chromosome abnormalities, levels of urinary catecholamines, and a range of 
biological markers. Since the early 1980s, tumor genetic information has been used to 
determine the prognosis of neuroblastoma patients (Maris 2010). Brodeur et al. were 
the first to identify the MYCN oncogene to be amplified in a large subset of primary 
untreated neuroblastomas and discovered a high correlation of this marker with an 
advanced stage of this cancer (Brodeur, Sekhon et al. 1977). Follow-up studies done by 
Seeger et al. demonstrated a strong association between rapid progression of the 
disease and a poor prognosis (Seeger, Brodeur et al. 1985). The MYCN oncogene was 
originally cloned in 1983 by identifying a portion of amplified sequence that was 
homologous to the MYC proto-oncogene (c-myc) (Kohl, Kanda et al. 1983; Schwab, 
Alitalo et al. 1983). Prevalent in about 20% of neuroblastoma cases, MYCN 
amplification is routinely used to determine subsequent treatment regimens (Schwab, 
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Alitalo et al. 1983; Brodeur, Seeger et al. 1984; Seeger, Brodeur et al. 1985). Although 
the occurrence of neuroblastoma is most often sporadic, there are some patients (1-2%) 
that have a family history of this cancer (Kushner, Gilbert et al. 1986; Maris, Kyemba et 
al. 1997). Recent reports demonstrate that activating mutations in the anaplastic 
lymphoma kinase (ALK) oncogene account for most hereditary cases of neuroblastoma 
(Mosse, Laudenslager et al. 2008). Furthermore, mutations in the homeobox gene 
PHOX2B can be prevalent in children with either sporadic or familial neuroblastoma in 
conjunction with congenital central hypoventilation syndrome (Mosse, Laudenslager et 
al. 2004; Trochet, Bourdeaut et al. 2004). 
A number of chromosomal aberrations have been identified to be associated with 
the incidence of neuroblastoma. In particular, Gilbert et al. first identified abnormalities 
on the long arm of chromosome 17; and gain of 17q genetic material has been 
recognized as the most common abnormality in primary neuroblastomas (Gilbert, Feder 
et al. 1984; Savelyeva, Corvi et al. 1994). In fact, unbalanced translocations between 
chromosomes 1 and 17 are common in primary neuroblastomas and result in loss of 
distal 1p with a gain in genetic information from 17q (Savelyeva, Corvi et al. 1994; Van 
Roy, Laureys et al. 1997). Moreover, it has been shown that addition of an intact human 
1p chromosome to a 1p-depleted neuroblastoma cell line induced cellular differentiation 
and/or death (Bader, Fasching et al. 1991). Other chromosomal deletions have been 
identified such as those on chromosome 11q and 14q. In many cases, it is suggested 
that tumor suppressors are contained within these deleted regions, thereby allowing for 
the progression of the primary neuroblastoma. 
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Tumor DNA index (DNA ploidy/ copy number) is one of the most common 
prognostic factors for determining staging of a neuroblastoma patient. Most 
neuroblastoma cell lines and advanced primary tumors have DNA content that is either 
near-diploid or near-tetraploid. Yet most patients that have a favorable outcome present 
with either hyperdiploid or near-triploid DNA content. Chromosomal rearrangements are 
typically associated with near-diploid or tetraploid, whilst hyperdiploid or near-triploid 
tumors commonly show whole chromosomal gains with few rearrangements (Maris and 
Matthay 1999). Several groups have identified alterations in gene expression that affect 
common cellular signaling pathways. Altered expression of neurotrophin receptors such 
as TRKA, TRKB, and TRKC have been associated with the prevalence of a 
neuroblastoma phenotype (Barbacid 1995). As members of the Trk family of tyrosine 
kinases, these receptors are essential to mediate the development of the sympathetic 
nervous system (Maris and Matthay 1999). Other potential mechanisms that underlie 
the incidence of neuroblastoma are the overexpression of multidrug resistance proteins 
(Norris, Bordow et al. 1996), evasion of apoptosis by overexpression of anti-apoptotic 
proteins such as BCL2 (Castle, Heidelberger et al. 1993; Hanada, Krajewski et al. 
1993), and increased telomerase expression (Hiyama, Hiyama et al. 1995). All of the 
above prognostic markers help clinicians to determine the stage of neuroblastoma and 
the appropriate course of treatment. 
TREATMENT 
According to the risk group a child falls into, patients will receive different 
regimens of treatment (American 2011). Children who present with low-risk 
neuroblastoma will typically receive only surgery for removal of the tumor. However, 
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depending on the success of removal or characteristics of the individual tumor, the child 
may receive short-term chemotherapy, radiotherapy, or both of these post-surgery. 
Intermediate-risk neuroblastoma patients are routinely prescribed 4 to 8 cycles of 
chemotherapy – and similarly to those at low-risk– supplemental radiotherapy if needed. 
High-risk children must endure the most rigorous treatment with a specific combination 
of all three (surgery, radiation, chemotherapy). In fact, treatment is divided into 3 distinct 
phases: induction, consolidation, and maintenance. Clinicians aim to first destroy as 
much tumor as possible, administering chemotherapy at doses higher than what is 
typically used in low- or intermediate-risk patients (induction). Second, the consolidation 
phase consists of ramping up the intensity of treatment to get rid of any lingering cancer 
cells that were not killed in the inuction phase. Last, children are given either retinoids 
(13-cis-retinoic acid) or immunotherapy in the maintenance phase to lessen the chance 
of tumor recurrence.  
Recurrence of tumors is an unfortunate but very real complication for many 
patients. In this case, a variation of, or more intense levels of surgery, chemotherapy, or 
radiotherapy regimens must be performed. Prognosis is often poor for neuroblastoma 
patients if diagnosis comes too late or in the case of tumor recurrence, because of 
decreased responsiveness to chemotherapy (Lasorella et al. 1995). New advances in 
neuroblastoma research have enabled clinicians to identify genetic markers, as 
described above, which are being explored now and “should be in use within the next 
few years” (Society 2011). For example, clinical trials are currently underway to 
investigate 1) the effectiveness of crizotinib (a protein kinase inhibitor) to inhibit the ALK 
pathway, 2) the ability of the monoclonal antibodies to target disialoganglioside GD2 in 
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neuroblastoma, and 3) the use of cancer vaccines to prompt the child’s own immune 
system to attack cancer cells. 
Our research is dedicated to investigating retinoid therapy, given to high-risk 
patients, and elucidating the role that reactive oxygen species (ROS) play in the 
differentiation of the SK-N-SH neuroblastoma cell line. Although 13-cis retinoic acid is 
the typical drug used clinically, all-trans retinoic acid (ATRA) is the ultimate metabolite in 
vivo and is one of the most potent inducers of differentiation for human neuroblastoma 
cells in vitro (Sidell, Altman et al. 1983). The following sections will highlight retinoids 
and their 1) history as a therapeutic agent, 2) metabolism, 3) mechanisms of action, and 
4) use as a means to differentiate various cancer types including neuroblastoma. The 
remainder of the section will 1) review redox biology and 2) emphasize the role of ROS 
and antioxidants to alter redox status of the cell and influence cellular processes such 
as differentiation. Much of this material has been reviewed and published recently by 
Silvis and Kiningham (Silvis and Kiningham 2012). 
RETINOIDS 
BACKGROUND 
Vitamin A is the parent compound of natural and synthetic retinoid metabolites. 
Retinoids comprise a family of structurally similar molecules (Figure 1.1) that exhibit a 
variety of antitumor effects such as inhibiting cellular proliferation (Altucci and 
Gronemeyer 2001), as well as inducing apoptosis (Altucci and Gronemeyer 2001), cell 
cycle arrest (Donato, Suh et al. 2007), and differentiation (Reynolds and Lemons 2001). 
Retinoids have been used as an anti-tumor agent against a variety of cancers including 
acute promyelocytic leukemia (APL) (Reynolds and Lemons 2001), neuroblastoma 
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(Reynolds and Lemons 2001), and cervical dysplasia (Meyskens, Surwit et al. 1994). 
Before the 1920s, all of the findings demonstrating the essential nature of Vitamin A 
were focused on its role in vision. Then in 1925, Wolbach and Howe demonstrated that 
rodents deficient in Vitamin A experienced squamous metaplasia in the trachea and 
other epithelial sites (Wolbach and Howe 1978); reintroduction of Vitamin A reversed 
this occurrence. In the 1950s and 1960s, Olsen described the metabolism of Vitamin A 
(Blaner and Olson 1994) which was followed by recognition of the importance of 
transport proteins both in the plasma (Goodman 1984) and within the cell (Ong, 
Newcomer et al. 1994). A wave of research ensued in the 1970s and 1980s once 
Saffiotti et al. demonstrated antitumor properties of Vitamin A in a lung cancer model 
(Saffiotti, Montesano et al. 1967). Retinoids were found to exhibit antitumor effects in 
other animal models such as hamsters (Chu and Malmgren 1965; Saffiotti, Montesano 
et al. 1967), mice (Davies 1967), and rabbits (McMichael 1965); however, at this time, 
clinical use was still controversial due to their lack of effectiveness in human cancers. In 
particular, all-trans retinoic acid (all-trans RA, ATRA, tretinoin) and 13-cis retinoic acid 
(13-cis RA, isotretinoin) were two of the major metabolites on which most of the 
research focused. All-trans RA is the endogenous ligand, whereas 13-cis RA is a 
synthetic retinoid that can be isomerized to ATRA (Figure 1.1). The effectiveness of 
both all-trans- and 13-cis RA as a therapeutic tool for APL was demonstrated in a 
primary human promyelocytic leukemia cell line (HL-60) (Breitman, Selonick et al. 
1980). Both of these retinoids were effective anti-tumor agents when used at 
concentrations much less than previously discovered differentiation-inducing therapies. 
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Clinically, APL was initially treated with 13-cis RA, and a majority of patients 
experienced complete remission (Daenen, Vellenga et al. 1986; Fontana, Rogers et al. 
1986). However, retinoid use in the clinic has been met with unfavorable outcomes such 
as 1) cellular toxicity which results in dryness/ inflammation of the lips (cheilitis) and skin 
(xerosis, dermatitis), plus 2) resistance to the retinoids themselves as a result of 
prolonged treatment (Fontana, Rogers et al. 1986). Subsequently, clinical trials showed 
ATRA to be very effective in many APL patients, where a majority experienced 
complete remission. However, a population of APL promyelocytes was isolated from a 
patient and found in vitro to exhibit resistance to retinoid treatment (Huang, Ye et al. 
1988). As a result of these clinical trials, new research ensued to investigate retinoid 
mechanisms of action. Discoveries of retinoid receptors surfaced (Kastner, Chambon et 
al. 1994; Mangelsdorf, Umesono et al. 1994) and scientists learned that ligand (i.e. 
retinoid) -receptor interactions could either activate or inactivate particular genes. 
Examples of target genes include: RAR important for retinoid signaling (de The, 
Vivanco-Ruiz et al. 1990); alcohol dehydrogenase (ADH3), essential for retinoid 
metabolism (Duester, Shean et al. 1991); and cellular retinol binding protein (mCRBPI), 
which binds and transports retinoids (Smith, Nakshatri et al. 1991).  
RETINOID METABOLISM 
Not only is Vitamin A metabolized into various structural forms, but there is much 
evidence to show that synthetic retinoids (i.e. Fenretinide) can elicit similar effects as 
endogenous ones. Furthermore, in any respective study, there is often debate as to 
which metabolite is biologically active, i.e. the one to which cellular effects can be 
scribed.  
  
 12  
 
Vitamin A cannot be synthesized endogenously but must be obtained in the diet. 
Animal-derived foods contain preformed Vitamin A that is predominantly in the form of 
retinyl esters; whereas plant-derived foods contain pro-vitamin A carotenoids, such as 
β-carotene (reviewed in (Lane and Bailey 2005; Barnard, Collings et al. 2009) (Figure 
1.1). A majority of this pro- and preformed Vitamin A is converted to all-trans retinol 
(Vitamin A) by a series of reactions that occur in the intestinal lumen and mucosa. 
Retinol can be re-esterified after absorption by enterocytes and then packaged into 
chylomicrons for transportation to and storage in the liver. According to the body’s 
needs, these retinyl esters are re-hydrolyzed to retinol, which is secreted from the liver 
bound to retinol binding protein (RBP). Once retinol reaches its target cell, it can be 
handled in a variety of ways. Retinol’s lipophilic nature allows it to freely diffuse across 
cellular membranes, or bound with RBP, it may signal through the cell surface receptor 
Stra6 (Kawaguchi, Yu et al. 2007). Retinol can then be reversibly converted to retinal by 
alcohol dehydrogenase (ADH), which is then irreversibly converted to the bioactive form 
ATRA via aldehyde dehydrogenase (AHD). All-trans RA can either be 1) metabolized 
into other forms such as the 9-cis retinoic acid, 13-cis retinoic acid isomers, or 4-oxo-
retinoic acid, or 2) translocated by cellular retinoic acid binding proteins (CRABP-I, -II) to 
the nucleus for binding to nuclear receptors. All-trans RA is the most potent and the 
main signaling retinoid in vivo. Not only has it been very effective to treat APL (Reynolds 
and Lemons 2001), but it is also used as an anti-cancer agent for other cancers 
including neuroblastoma (Reynolds and Lemons 2001), and medulloblastoma 
(Gumireddy, Sutton et al. 2003). Metabolism (i.e. double-bond isomerization and 
oxidation) of endogenous retinoids can sometimes result in deleterious effects such as 
  
 13  
 
a decrease in activity and selectivity. Therefore, scientists have attempted to overcome 
these limitations by constructing synthetic retinoids which are often more stable and 
more active (Barnard, Collings et al. 2009).  
  
FIGURE 1.1: NATURALLY OCCURRING RETINOIDS   
β-carotene, found in plant-derived foods, is cleaved to form two molecules of retinal. 
Retinyl esters (R: fatty acid), found in animal-derived foods, are hydrolyzed to retinol. 
Retinol is reversibly converted to retinal by alcohol dehydrogenase (ADH). Retinal is 
irreversibly converted to ATRA via aldehyde dehydrogenase (AHD). ATRA can be 
isomerized into 9-cis retinoic acid or 13-cis retinoic acid. ATRA can also be irreversibly 
oxidized to form metabolites such as 4-oxo-retinoic acid by cytochrome P450 2D6. 
SDR, short-chain dehydrogenase.   
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RETINOID MECHANISM OF ACTION 
The biological actions of retinoids are mediated in part by heterodimerization of 
nuclear retinoic acid receptors (RAR-, -, and -) and retinoid “X” receptors (RXR-, -
, and -). Each subtype of the receptor is encoded for by different genes that have 
multiple promoters, and each product can undergo differential splicing. Therefore, the 
array of isoforms that exist between RARs and RXRs gives rise to many potential 
combinations of receptor dimers (Lane and Bailey 2005). The ligand specificities of 
these receptors differ. All-trans- and 9-cis-RA can bind to the RARs, but RXRs only bind 
9-cis-RA (Heyman, Mangelsdorf et al. 1992; Levin, Sturzenbecker et al. 1992). Affinities 
for various receptors differ also in the fact that RARs bind ATRA with higher affinity than 
9-cis RA (Soprano, Qin et al. 2004). The metabolite 13-cis RA can either bind to RAR in 
its native configuration (Idres, Marill et al. 2002), or bind in the form of ATRA after 
isomerization (Tsukada, Schroder et al. 2000). Once bound by a ligand, the RAR-RXR 
heterodimer binds to the retinoic acid response element (RARE); whereas RXR 
homodimers bind to rexinoid response elements (RXREs) (Soprano, Qin et al. 2004) 
Retinoic acid can bind with high affinity to another receptor (peroxisome proliferator-
activated receptors, PPARβ/γ) (Shaw, Elholm et al. 2003), which also functions as a 
heterodimer with RXR (Laudet and Gronemeyer 2002). RXR-PPAR heterodimers bind 
as a complex to the peroxisome proliferator response element (PPRE). All-trans RA 
binding to PPAR receptors has been suggested to promote cell survival (Schug, Berry 
et al. 2007) and to mediate RA resistance (Schug, Berry et al. 2008) in mammary 
mouse carcinomas.  
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Retinoids can indirectly regulate a number of genes that are targets of regulatory 
proteins (i.e. transcription factors) whose expression is directly controlled by activated 
RAR/RXR. Therefore, these secondary genes are susceptible to retinoid-regulation, 
even though they do not possess a RARE. All-trans RA can also exhibit non-receptor 
mediated effects such as activation of transcription factors that do not bind the RARE 
(Salbert, Fanjul et al. 1993; Li, Dong et al. 1996) or changes in redox balance within a 
cell (Mantymaa, Guttorm et al. 2000), which is the focus of our work and will be 
discussed in greater detail in the subsequent section.  
The common means by which retinoids are known to antagonize carcinogenesis 
are either by inducing differentiation and apoptosis and/ or suppressing proliferation. 
Current research efforts are devoted to identifying the exact mechanisms by which 
retinoids accomplish these actions. Moreover, there is a vast difference amongst 
studies regarding the type of retinoids (natural vs. synthetic), concentration (micromolar 
range), the duration of treatment (days to weeks), and the particular model (in vitro, in 
vivo, ex vivo). The various retinoid metabolites can elicit different cellular responses. For 
example, 9-cis RA is a very effective differentiation agent for neuroblastoma cells in 
vitro (Lovat, Irving et al. 1997; Lovat, Irving et al. 1997), however the toxicity of 9-cis RA 
in vivo may limit its clinical potential (Ponthan, Borgstrom et al. 2001). Cells cultured in 
vitro experience much less toxicity with ATRA; however, its effectiveness has been 
limited by a short half-life and decreased plasma levels due to drug metabolism 
(Reynolds and Lemons 2001). Nonetheless, scientists have been dedicated to 
optimizing retinoid therapy in ways such as decreasing toxic side effects (Hansen, Wylie 
et al. 2007), increasing bioavailability (Van Heusden, Van Ginckel et al. 2002; 
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Armstrong, Ruiz et al. 2005), and even enhancing effectiveness by co-administration of 
other agents such as carsonic acid (a phenolic antioxidant derived from rosemary) and 
prostaglandin D2 (Danilenko, Wang et al. 2001; Passeron, Valencia et al. 2009). 
RETINOID EFFECTS ON DIFFERENTIATION 
Acute promyelocytic leukemia (APL) is the original and most widely studied 
cancer model for which differentiation therapy with ATRA is used (Huang, Ye et al. 
1988; Castaigne, Chomienne et al. 1990). APL is characterized by the prevalence of a 
fusion protein (PML-RARα) due to a t(15;17) chromosomal translocation (de The, 
Chomienne et al. 1990; de The, Lavau et al. 1991). The PML-RARα fusion protein 
generates a block such that RARα is unable to transcriptionally regulate essential genes 
involved in differentiation when heterodimerizing with RXR. ATRA therapy is believed to 
induce promyelocytic differentiation by degradation of the PML-RARα fusion protein via 
binding to its receptors (Zhang, Wang et al. 2000). However, there is evidence to 
suggest that ATRA can also induce APL cells to differentiate in a RAR-independent 
manner (Benoit, Altucci et al. 1999). The alternate differentiation response may involve 
cross-talk between RXR agonists and protein kinase A. Not only have retinoids been 
proven effective against APL, but clinical trials within the past decade have 
demonstrated successful treatment of juvenile malignancies such as neuroblastoma 
(Matthay, Villablanca et al. 1999). As stated before, neuroblastoma is the most common 
extracranial solid tumor in childhood, representing 7-10% of all pediatric cancers. A 
number of retinoids have been used in clinical trials to fight this childhood cancer 
including 13-cis RA, 9-cis RA, ATRA, and synthetic homologues such as fenretinide 
(Reynolds and Lemons 2001). There are many mechanisms proposed for the 
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effectiveness of retinoids on various neuroblastoma models. Much work to date has 
focused on retinoid-mediated gene regulation through the RARs; however, there are 
reports to suggest some effects to be a result of receptor-independent mechanisms. 
Any such action of retinoids can be the result of activation of both pathways.  
 
PHYSIOLOGICAL ROLE OF CELLULAR REDOX STATE 
BACKGROUND 
The first exploration of free radicals in a biological system was by Denham 
Harman (Harman 1956), who proposed that they play an essential role in the aging 
process. His work helped to pioneer ensuing research on free radicals and their 
importance in living systems. As early as 1969, McCord and Fridovich discovered 
superoxide dismutase (SOD) (McCord and Fridovich 1969), which was followed by 
studies showing that both the enzyme and hydroxyl radical (•OH) could stimulate the 
second messenger cyclic guanosine monophosphate (cGMP) (Mittal and Murad 1977). 
Since then, there have been decades of research to demonstrate that not only have 
living systems adapted to the existence of free radicals, but they developed ways to 
either counter their existence or use them as signaling molecules. The redox status of a 
cell (determined by the balance of ROS and antioxidants) can influence and regulate a 
multitude of cellular processes including proliferation, differentiation, and death 
(Mantymaa, Guttorm et al. 2000; Tsatmali, Walcott et al. 2006; Reddy, Kleeberger et al. 
2008). Because of this fact, it is necessary to investigate the relative contributions both 
ROS and antioxidants make in any particular system. 
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REACTIVE OXYGEN SPECIES (ROS)/ REACTIVE NITROGEN SPECIES (RNS) 
Interestingly, ROS represent a biological paradox. They are essential to prevent 
disease directly (i.e. antibiotic-triggered ROS) (Goswami, Mangoli et al. 2006) and by 
initiating signaling cascades (i.e.) to promote apoptosis; however, increased levels have 
the potential to damage important macromolecules and thus may play a role in 
promoting carcinogenesis (Seifried, Anderson et al. 2007). Reactive oxygen species are 
characterized as oxygen containing molecules that have a high reactivity with 
neighboring molecules. Among the most prominent ROS are the superoxide anion (O2
•), 
hydrogen peroxide (H2O2), the hydroxyl (
•OH) and peroxyl (ROO•) radicals, and peroxyl 
(Figure 1.2). Under physiological conditions, nearly 1-3% of electrons flowing through 
the electron transport chain “leak” into the mitochondrial matrix and contribute to the 
formation of O2
• (Chance, Sies et al. 1979; Cadenas and Sies 1998). Although this 
phenomenon represents the bulk of O2
• formation, a portion is also produced via the 
reduction of molecular oxygen by NAD(P)H oxidases (Ushio-Fukai 2006; Brown and 
Griendling 2009) or by xanthine oxidase (Muller, Lustgarten et al. 2007), which are 
typically located in either the plasma membrane or the cytosol, respectively. Hydrogen 
peroxide is another major ROS which can be generated by the mitochondria, 
microsomes and/or peroxisomes (Chance, Sies et al. 1979). Its longer half-life either in 
the mitochondrial matrix or the cytosol render it available to act as a key signaling 
molecule. Signaling functions of O2
• and H2O2 will be discussed in greater detail under 
the “ROS AND SIGNAL TRANSDUCTION” section as they pertain to modulation of 
ROS-responsive transcription factors (i.e. NF-κB, AP-1, and Nrf2). 
The hydroxyl radical has extremely high reactivity, making it a very dangerous 
ROS against cells. Because of its short half-life, •OH reacts close to the site of its  
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FIGURE 1.2: PATHWAYS OF ROS FORMATION AND DEGRADATION 
Electrons (e
-
) flow through the electron transport chain (complexes I, II, III, IV) and 
generate a proton (H
+
) gradient which drives the formation of ATP. During this process, 
electrons leak into the mitochondrial matrix and contribute to the generation of 
superoxide anion (O2
•). Manganese superoxide dismutase (MnSOD) scavenges O2
• 
and produces hydrogen peroxide (H
2
O
2
), which can be degraded by a number of 
enzymes including catalase, glutathione peroxidase (GPx) and peroxiredoxins (Prdx). 
In the presence of nitric oxide radical (NO•), O2
• can also be converted into 
peroxynitrite (ONOO-) Small disulphide-containing proteins (TrxS
2
) can be reduced by 
thioredoxin reductase (TrxR). OM: Outer mitochondrial membrane; IM: Inner 
mitochondrial membrane; NADPH: Nicotinamide Adenine Dinucleotide Phosphate; 
GSH: Reduced glutathione; GSSG: Oxidized glutathione; O
2
 Molecular oxygen; Pi: 
Inorganic phosphate.  
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formation (Pastor, Weinstein et al. 2000). Tight regulation of free intracellular iron levels 
is also crucial due to the fact that Fe2+ can participate in the Fenton reaction with H2O2 
to produce •OH (Fe2+ + H2O2  Fe
3+ + •OH + OH-) (Fenton 1894). In fact, excess levels 
of O2
• under stress conditions has been shown to release free iron from molecules such 
as the [4Fe-4S] cluster-containing enzymes of dehydratases (Liochev and Fridovich 
2002). Therefore, O2
• facilitates •OH production via the Haber-Weiss reaction (O2
• + 
H2O2  O2 + 
•OH + OH-) as described by the combination of the Fenton reaction and 
the reduction of Fe3+ by O2
• (Fe3+ + O2
•   Fe2+ + O2) (Haber and Weiss 1932; Liochev 
and Fridovich 2002). Last, but not least, the most basic ROO• is the protonated form of 
O2
•, hydroperoxyl radical, (HOO•), which represents only ~0.3% of cytosolic O2
• (De 
Grey 2002) and is well established to initiate fatty acid/ lipid peroxidation (Aikens and 
Dix 1991).  
Reactive nitrogen species (RNS) (Oberley, Ridnour et al.) are a source of 
nitrosative stress that also contributes to the overall redox status of a cell. Being the 
most prominent, the nitric oxide radical (NO•) is a small molecule that is generated by 
nitric oxide synthases (NOSs) (Ghafourifar and Cadenas 2005) and can also act as an 
important signaling molecule in neurotransmission, blood pressure regulation, smooth 
muscle relaxation, and immune defenses (Bergendi, Benes et al. 1999). Moreover, a 
large amount of both NO• and O2
• react together to produce a much more highly 
reactive molecule, peroxynitrite (ONOO-), which participates in DNA fragmentation and 
lipid oxidation (Carr, McCall et al. 2000), plus apoptosis in several cell types including 
PC12 cells (Shacka, Sahawneh et al. 2006) and cortical neurons (Bonfoco, Krainc et al. 
1995). Additionally, ONOO- also targets tyrosine residues in proteins; and increased 
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nitrotyrosines are a common characteristic in neurodegenerative disorders (reviewed in 
(Beckman and Koppenol 1996)). The rate of OONO- formation in the presence of NO• 
and O2
• is three times faster (6.7 x 109 M-1 s-1) than the enzymatic conversion of O2
• by 
SOD (2 x 109 M-1 s-1). Therefore high concentrations of NO• or a lack of SOD could 
essentially drive the formation of the toxic oxidant ONOO- versus the production of the 
less reactive oxidant H2O2 (Figure 1.2) (Beckman and Koppenol 1996). 
ANTIOXIDANTS 
Exposure to a variety of oxidative stimuli has precipitated the need for cellular 
defense mechanisms to keep the levels of ROS in check. Such a response involves the 
presence of antioxidants: some of which are enzymatic (SODs, catalase, and 
glutathione peroxidase (GPx)) and others of which are not (glutathione (GSH), other 
thiols, and vitamins). In the human species, the superoxide dismutase (SOD) enzyme 
exists as three different isoforms, distinguished structurally in the nature of the active 
metal center, number of subunits, and necessary cofactors. Each of them catalyzes the 
dismutation of O2
• to O2 and the less reactive H2O2; however, they are distributed in 
different subcellular compartments (Oberley and Oberley 1988). Located in the 
mitochondria, MnSOD has been shown by Fridovich and others to be necessary for 
survival in all oxygen-metabolizing cells (McCord, Keele et al. 1971). Upon inactivation 
of this isoform, homozygous mutant mice cannot survive and die within the first 10 days 
of life due to dilated cardiomyopathy and neurodegeneration (Li, Huang et al. 1995; 
Lebovitz, Zhang et al. 1996). Not only does MnSOD function to protect cells from the 
toxicity of ROS, but also 1) is typically down-regulated in transformed cells in 
comparison to normal cells (Yamanaka and Deamer 1974), 2) plays an important role 
  
 22  
 
as a tumor suppressor via attenuating radiation-induced transformation by 
overexpression (St Clair, Wan et al. 1992), and 3) is believed to be important in the 
process of differentiation (St Clair, Oberley et al. 1994; Erlejman and Oteiza 2002).  
The copper-zinc superoxide dismutase (CuZnSOD) isoform is located in the 
cytosol and its activity is also usually lower in cancer cells (Oberley and Buettner 1979). 
Moreover, this enzyme is suggested to possess tumor suppressor capabilities in human 
gliomas (Zhang, Zhao et al. 2002). Extracellular superoxide dismutase (EcSOD) is the 
secreted isoform whose importance is most prominent in the lung. EcSOD knock-out 
mice suffer severe lung damage (Carlsson, Jonsson et al. 1995) and recent studies 
suggest that the loss of EcSOD in lung cancer cells contributes to remodeling of the 
extracellular matrix and enhanced malignancy. The secreted form can also bind to 
glycoproteins such as heparin and heparin sulfate (Mates, Perez-Gomez et al. 1999). 
The role of EcSOD in carcinogenesis has not been extensively studied; however it 
remains an important regulator of extracellular O2
• levels and therefore subsequent 
signaling pathways influenced by this ROS (Kinnula and Crapo 2004).   
Catalase is found predominantly in peroxisomes and is very efficient in 
scavenging H2O2 and converting it to water and molecular oxygen (O2). Having one of 
the highest turnover rates amongst antioxidant enzymes, catalase activity is also 
typically low in tumors, contributing to the inability of cancer cells to detoxify increases in 
H2O2 (Valko, Rhodes et al. 2006). Glutathione peroxidase (GPx) is also important for 
scavenging peroxides (i.e. H2O2, ROOH) and preventing 
•OH formation via the Fenton 
reaction. The GPx antioxidant enzyme exists in two different forms: that which is 
selenium-dependent (glutathione-S-transferase (GST)) and those of which are 
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selenium-independent (GPx’s) (Burk, Nishiki et al. 1978). Humans have four distinct 
GPx enzymes, which in the presence of its cofactor glutathione (GSH), catalyzes 
peroxide reduction whilst simultaneously oxidizing GSH to form two glutathione 
molecules bound by a disulfhydryl bond (GSSG). Demonstrated in Figure 1.2, both 
catalase and GPx scavenge H2O2. However, catalase has a lower affinity for H2O2 and 
is generally accepted to be required in the presence of high H2O2 concentrations 
(Jones, Eklow et al. 1981). Cytosolic GPx (GPx1) is considered to be the major isozyme 
responsible for degradation of H2O2 (Li, Yan et al. 2000). Furthermore, increased GPx1 
activity has been shown to suppress H2O2-induced apoptosis in both hematopoietic and 
kidney cells (Hockenbery, Oltvai et al. 1993; Kayanoki, Fujii et al. 1996). Maintenance of 
low levels of intracellular H2O2 is also achieved by a family of peroxiredoxin enzymes (6 
isoforms) that possess a highly conserved cysteine residue that functions by reducing 
not only hydroperoxides but also ONOO-.  
Glutathione is the predominant non-protein thiol in the cell and is perhaps the 
most essential factor in maintaining cellular redox homeostasis. As stated above, it 
exhibits antioxidant properties by reducing H2O2, various hydroperoxides (ROOH), and 
lipid peroxides via acting as a substrate in the GPx reaction. The GSSG that is 
subsequently formed can either be excreted from the cell or reduced back to GSH 
(Dickinson and Forman 2002). GSH can also be used in conjugation reactions with GST 
as a means to rid the cell of deleterious exogenous compounds. Glutathione is a 
tripeptide (glutamate-cysteine-glycine) that is synthesized from its constituent amino 
acids in two enzymatic steps. The first enzymatic reaction involves glutamate cysteine 
ligase (GCL), which consists of a modulatory (GCLM) and a catalytic subunit (GCLC). 
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Glutamate cysteine ligase catalyzes the reaction between glutamate and cysteine and is 
the rate limiting enzyme for GSH-biosynthesis. The second enzymatic reaction with 
glutathione synthase (GS) is responsible for the addition of glycine (Dickinson and 
Forman 2002). A number of studies investigated the importance of the Nrf2-GSH 
system to control cell survival. Of the most notable enzymes under Nrf2 control are the 
aforementioned GSH-biosynthesizing enzymes (McMahon, Itoh et al. 2001). Reddy et 
al. demonstrated that 1) GSH supplementation rescued the proliferative defects in Nrf2 
deficient lung epithelial cells (Reddy, Kleeberger et al. 2007) and 2) GSH depletion 
using buthionine sulfoximine (BSO) enhanced oxidative stress and decreased 
proliferation of alveolar epithelial cells (Reddy, Kleeberger et al. 2008). Furthermore, the 
combination of ATRA and BSO had a more marked effect on inhibition of clonogenic 
growth in acute myelocytic (AML) cells than did either alone (Mantymaa, Guttorm et al. 
2000). Although existing at much lower concentrations than GSH, thioredoxin (TRX) is a 
small disulphide-containing protein (TrxS2) which can undergo redox reactions with 
multiple substrates. Reduction of the oxidized form (TrxS2) is catalyzed by the enzyme 
thioredoxin reductase (TrxR) in the presence of NADPH (Valko, Rhodes et al. 2006). 
Manipulation of ROS with exogenous antioxidants is a common method by which 
to modulate the intracellular redox state. The variety of antioxidants possess distinctive 
qualities, especially based on their water/or lipid solubility, which influences intracellular 
compartmentalization. Furthermore, antioxidant concentration factors into their 
biological effects due to the pro-oxidant capacity of these molecules when used in 
excess. The focus of Chapter 2 is an investigation of the therapeutic uses of N-acetyl-L-
cysteine (NAC) when used in combination with ATRA in the SK-N-SH neuroblastoma 
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cell line. The antioxidant capacity of NAC can be attributed to its ability to scavenge free 
radicals, act as a substrate for glutathione (GSH) synthesis, and/or directly reduce 
hydroperoxides and protein disulfides (Parasassi, Brunelli et al. 2010). NAC is already 
used clinically: for treatment of acetaminophen toxicity (Whitehouse, Wong et al. 1981) 
or as an adjuvant in respiratory conditions with excessive mucus production (De Lisle, 
Roach et al. 2007). Our work combined with the documented beneficial and safe uses 
of NAC in the clinic, suggest that a thiol supplement may be beneficial when 
administered in combination with retinoids to improve neuroblastoma differentiation 
therapy. Future studies may also include additional redox modifying agents (such as 
Vitamin C, Vitamin E, or phenolic compounds)) to see if they influence differentiation in 
this cell line. 
As discussed above, studies have shown that the redox status plays a very 
important role in mediating processes such as differentiation, growth, apoptosis, and 
proliferation. In light of the focus of our research being differentiation, each of these will 
not be discussed in detail. However, the following section will review the effects of the 
redox status on a number of signal transduction pathways; each of them playing 
important roles in cancer models. 
ROS AND SIGNAL TRANSDUCTION 
There are several transcription factors whose activation is dependent on the presence 
of ROS. Figure 1.3 depicts three most common redox sensitive transcription factor 
pathways (NF-κB, AP-1, and Nrf2), their classic means of activation, and potential 
cross-talk between them. NF-κB is a multiprotein complex that regulates many genes 
involved in inflammation, cell survival, and even differentiation (Hayden and Ghosh  
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FIGURE 1.3: REDOX SENSITIVE TRANSCRIPTION FACTORS  
Activation pathways for three classic transcription factors (NF-κB, AP-1, and Nrf2) in 
the presence of ROS (reactive oxygen species) stimuli. ROS are not simply by-
products of enzymatic reactions; but function as signaling molecules to modulate 
pathways involved in proliferation, growth, apoptosis, differentiation, etc. As depicted, 
each pathway (and others not shown) is involved in crosstalk, collectively influencing 
cellular response to ROS. MAPKs: mitogen-activated protein kinases; ERK1/2: 
extracellular related kinase 1/2; JNK: c-Jun-N-terminal kinase; p38: p38 MAPK; CRE: 
cAMP response element; IKK: inhibitory kappa B kinase; IκB: inhibitory kappa B; NF-
κB: nuclear factor kappa B; κB: kappa B response element; Nrf2: nuclear factor E2-
related Factor 2; Keap1: kelchlike ECH associated protein 1; sMaf: small Maf protein; 
ARE: antioxidant response element; P: phosphate; Ub: ubiquitin. 
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2008). Comprised of a heterodimer of p50 and p65 polypeptides, inactive NF-κB resides 
in the cytoplasm bound to inhibitory kappa-B (IκB). The classical pathway is activated 
by stimuli (i.e. interleukin-1β, TNF-α, viruses, TPA, UV light, ionizing radiation, ROS) 
that cause IκB phosphorylation, and subsequent release and translocation of the p50-
p65 heterodimer to the nucleus. Entry of NF-κB into the nucleus is followed by DNA 
binding and induction of mRNA synthesis of target genes reviewed in (Genestra 2007). 
It is well established that ROS-mediated activation of NF-κB and its target genes is an 
adaptive response to attenuate oxidative stress and promote cell survival (Morgan and 
Liu 2011). For example, NF-κB activation can upregulate antioxidant enzymes such as 
MnSOD, CuZnSOD, GST-pi, and GPx (Xia, Hu et al. 1996; Djavaheri-Mergny, Javelaud 
et al. 2004; Rojo, Salinas et al. 2004; Schreiber, Jenner et al. 2006). Moreover, 
Kiningham and colleagues have previously demonstrated an NF-κB element within the 
second intron of the SOD2 gene that was essential to cytokine- and phorbol ester- 
activation of MnSOD (Xu, Kiningham et al. 1999; Kiningham, Xu et al. 2001). In 
addition, the specificity of H2O2 to signal NF-κB activation stems from studies showing 
that overexpression of catalase, but not SOD, decreased NF-κB activity in mouse 
epidermal cell lines (Schmidt, Amstad et al. 1995). Subcellular localization of ROS also 
differentially influences NF-κB activation; whereby cytoplasmic sources stimulate its 
activation (i.e. H2O2), but nuclear generation can inhibit it (i.e. NO) (Kabe, Ando et al. 
2005).  
 NF-κB is demonstrated to be important particularly during neurogenesis (O'Neill 
and Kaltschmidt 1997). In addition to our publication showing reduced NMDAR1 
expression by blocking NF-κB p50 translocation (Kiningham, Cardozo et al. 2008), 
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Kania et al. indicate that IL-1 upregulation induced binding activity of NF-κB in retinoic 
acid differentiation of SH-SY-5Y cells (Kania, Baranska et al. 2003). This increase was 
coupled with stimulated MnSOD activity. Feng et al. also demonstrated increased NF-
κB activity prior to differentiation of SH-SY-5Y cells, which was blocked in the presence 
of a dominant negative NF-κB inhibitor (Feng and Porter 1999). 
 In addition to NF-κB, AP-1 transcription factor proteins, c-jun and c-fos, are 
induced by ROS such as reactive radicals (O2
•) (Maki, Berezesky et al. 1992) and H2O2 
(Aggeli, Gaitanaki et al. 2006). In response to oxidative stress, AP-1 is activated mainly 
by the MAPK (mitogen-activated protein kinase) signaling pathways such as 
extracellular signal-related protein kinase (ERK), c-Jun-N-terminal kinase (JNK) and 
p38 MAPK (Surh, Kundu et al. 2005). AP-1 is most often associated with increased cell 
proliferation (Shaulian and Karin 2001). Devary et al. show that ROS generation via 
ultraviolet light increased DNA-binding activity of AP-1 in HeLa cells, and suggest that 
this mediated the induction of other DNA-damage-response genes (Devary, Gottlieb et 
al. 1991). Demonstrating the specificity of this transcription factor, ROS-mediated 
activation of AP-1, but not NF-κB, inhibited glutamate-induced apoptosis in HT4 
neuronal cells (Aharoni-Simon, Reifen et al. 2006). Nonetheless, AP-1 and NF-κB 
subunits participate in crosstalk. Physical interaction of the NF-κB p65 subunit with 
either Jun or Fos proteins enhances DNA binding and activation of both NF-κB and AP-
1 response elements in HeLa cells (Stein, Baldwin et al. 1993). Similar to the interaction 
of NF-κB and MnSOD, there is an AP-1 DNA binding sequence in the human SOD2 
gene promoter (Zhang 1996). As cited above, MnSOD plays an important role as a 
tumor suppressor (St Clair, Wan et al. 1992). To elucidate this mechanism, Li et al. 
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developed transient and stable transfectants of MCF-7 breast cancer cells 
overexpressing MnSOD and investigated AP-1 and NF-κB activity (Li, Oberley et al. 
1998). Interestingly, TPA-mediated induction of the MnSOD gene decreased both AP-1 
and NF-κB activity. However, transient transfection with the MnSOD gene resulted in 
transactivation of NF-κB, only in the presence of low concentrations (1 mM) of sodium 
pyruvate (H2O2 scavenger). Alternatively, stable MnSOD-overexpressing transfectants 
required high concentrations of sodium pyruvate (10 mM) to survive. Therefore, these 
data suggested that the relative levels of H2O2 generated by MnSOD in either instance 
was a contributing factor of NF-κB activation. Excess H2O2 induced toxicity whilst very 
low amounts did not induce NF-κB activation. These findings are pertinent to our studies 
by demonstrating the balance of O2
• and H2O2 that is maintained by MnSOD and how 
this can affect downstream targets. In contrast, Kiningham et al. published opposite 
findings in fibrosarcoma cells where MnSOD overexpression instead selectively 
decreased AP-1 binding capacity (and not NF-κB) (Kiningham and St Clair 1997).  
 The wide variety of proteins in the Jun- (c-Jun, JunB, JunD) and Fos-families (c-
Fos, FosB, Fra-1, Fra-2) can form multiple heterodimers that are capable of regulating a 
plethora of cellular processes, including differentiation (Eriksson, Taskinen et al. 2007). 
Studies in PC12 neuronal cells demonstrate the effects of c-Jun to be dependent of 
their differentiation status. For example, c-Jun stimulates differentiation of neuronally 
immature cells, yet induces apoptosis in those that are differentiated (Xia, Dickens et al. 
1995; Heasley, Storey et al. 1996; Leppa, Eriksson et al. 2001). c-Fos is also shown to 
be required for elongation of neurite processes (Gil, Bussolino et al. 2004).  
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Another central mediator of oxidative stress is the nuclear transcription factor 
Nrf2, which is essential in regulating expression of antioxidant enzymes that respond to 
increases in ROS. In fact, Nrf2 knockout mice are more sensitive to toxic agents, 
hyperoxia, and carcinogens (Enomoto, Itoh et al. 2001). Not only is this transcription 
factor activated in the presence of ROS like H2O2, but it is also activated by chemical 
compounds that have the ability to undergo redox cycling or be metabolized into an 
electrophilic intermediate (Rushmore, King et al. 1990; Rushmore, Morton et al. 1991). 
As stated above, Nrf2 is the master regulator of GSH-synthesizing enzymes (GCL and 
GS). Nrf2 binds to an antioxidant response element (ARE) in 5’-flanking promoter 
regions of target genes as a heterodimer with small Maf (musculoaponeurotic 
fibrosarcoma virus) proteins (Nioi, McMahon et al. 2003). Under normal homeostatic 
conditions, Nrf2 activity is repressed by inhibitory factor Kelchlike ECH associated 
protein 1 (Keap1), a substrate adaptor for the Cul3/Rbx1 E3 ubiquitin ligase (McMahon, 
Thomas et al. 2006). Ubiquitination of Nrf2 is inhibited by oxidative modification of 
specific cysteine residues in Keap1 (Wakabayashi, Dinkova-Kostova et al. 2004). 
Consequently, Keap1 inactivation allows Nrf2 accumulation in the nucleus where it 
forms a heterodimer with other bZIP proteins to transactivate genes including GSH 
biosynthesizing enzymes (Devling, Lindsay et al. 2005). As one would expect, the Nrf2 
pathway does not function alone; it is involved in crosstalk with other signaling pathways 
to influence the cellular response to oxidative stress. For example, in mouse embryonic 
fibroblasts, LPS-induction of NF-κB activity is increased in Nrf2-deficient cells versus 
wild-type (Thimmulappa, Lee et al. 2006). On the contrary, the p65 subunit of NF-κB 
reportedly represses the Nrf2-ARE pathway via a direct interaction with Keap1 activity 
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(Yu, Li et al. 2011). Increased Keap1 nuclear translocation resulted in dissociation of 
Nrf2 from the ARE, thereby inhibiting activity.  Furthermore, the role of Nrf2 in regulation 
of basal expression of endogenous antioxidants was investigated in cardiac fibroblasts. 
Zhu et al. showed lower basal levels of catalase, GSH, glutathione reductase, and GST 
in Nrf2-/- mice than in the wild type control. Moreover, induction of these antioxidants 
and total SOD activity by 3H-1,2-Dithiole-3-thione (D3T: chemoprotective agent) was 
abolished in Nrf2-/- cells (Zhu, Itoh et al. 2005). These findings strongly implicate an 
essential role of Nrf2 for SOD regulation.  
 The importance of Nrf2 in neuronal differentiation has not been extensively 
examined. Reddy et al. have done a number of studies demonstrating the importance of 
the Nrf2-GSH system to control cell survival in other cell types. The Nrf2-GSH system is 
believed to be an essential mediator of cellular proliferation because GSH 
supplementation rescued the proliferative defects in Nrf2 deficient lung epithelial cells 
(Reddy, Kleeberger et al. 2007). This group also reports that GSH depletion using 
buthionine sulfoximine (BSO) enhanced oxidative stress and decreased proliferation of 
alveolar epithelial cells (Reddy, Kleeberger et al. 2008). Zhao et al. show that retinoic 
acid upregulates the Nrf2 antioxidant response system within 24 hrs in the SH-SY-5Y 
cells (Zhao, Wu et al. 2009). In contrast, Wang et al. demonstrated a direct retinoic acid 
receptor (RAR)mediated effect by showing that ATRA caused suppression of Nrf2 
activity by liganded RAR, inhibiting recruitment of Nrf2 to the ARE in MCF-7 breast 
cancer cells (Wang, Hayes et al. 2007). Therefore, in consideration of the above 
studies, it is essential to examine in vitro culture conditions and take into account 
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cellular context (i.e. type of cell, differentiated state, RA concentration, level of cross-
talk) for each of these transcription factors. 
Altogether, it is essential to appreciate that there is an intricate network of 
oxidants (ROS/ RNS) and antioxidants that define the redox status of the cell. In 
addition, ROS are not simply by-products of enzymatic reactions; but are proven to 
function as important signaling molecules to modulate pathways that direct basic 
cellular processes (i.e. proliferation, growth, apoptosis, and differentiation). Adding to 
this complexity, each of these signaling pathways (and more that are not mentioned 
here) are involved in crosstalk, which influences how a particular cell responds in the 
presence of oxidative stress. 
MANGANESE SUPEROXIDE DISMUTASE (MNSOD), REACTIVE OXYGEN SPECIES, AND 
DIFFERENTIATION 
There is much evidence to support a role for the MnSOD enzyme in cellular 
differentiation. As reported by Oberley and Oberley, absolute MnSOD activity within a 
tumor is not necessarily low. However, activity is typically low in comparison to the 
normal differentiated cell type from which the tumor originates (Oberley and Oberley 
1988). There is key experimental evidence for the role of MnSOD in differentiation. 
Transfection of human MnSOD cDNA into mouse 10T1/2 embryonic cells enhanced 5-
azacytidine mediated differentiation (St Clair, Oberley et al. 1994), and that 
overexpression of MnSOD in mouse fibrosarcoma cells attenuates apoptosis and, 
conversely, promotes a more differentiated phenotype (Zhao, Kiningham et al. 2001). 
Moreover, MnSOD activity is reportedly increased in differentiated IMR-32 
neuroblastoma cells as compared to the undifferentiated progenitors (Erlejman and 
Oteiza 2002). In contrast to our studies performed with retinoids, this latter study uses 
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dibutyryl cAMP and 5-bromo-deoxyuridine to stimulate differentiation. The observed 
biological effect may be a result of different signaling mechanisms. Nonetheless, the 
prevalence of MnSOD in the more differentiated IMR-32 cultures contributes to the 
hypothesis that this isoform is indeed important in the differentiation process of 
neuroblastoma. 
There are a number of classic reagents used in vivo and in vitro to differentiate 
neuroblastoma: including but not limited to phorbol esters such as 12-O-
tetradecanoylphorbol-13-acetate (TPA, PMA), retinoids (ATRA, 13-cis RA), and growth 
factors (FGF, PDGF, EGF). Pahlman et al. demonstrate that although growth factors 
such as fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and  
epidermal growth factor (EGF) are mitogenic when used alone, they act synergistically 
with TPA to promote neuroblastoma differentiation (Pahlman, Hoehner et al. 1995). The 
aforementioned reagents share common mechanisms of action, but they also initiate 
unique signaling pathways to influence differentiation (Pahlman, Ruusala et al. 1984; 
Pahlman, Hoehner et al. 1995; Carlson, Pahlman et al. 2008). Furthermore, because 
the degree of sympathetic neuronal differentiation affects the outcome of neuroblastoma 
(Edsjo, Holmquist et al. 2007), it is essential to understand these mechanisms of action 
to improve pharmacological use of the compounds. Both TPA and retinoids have been 
shown to upregulate MnSOD in various cellular models (Mantymaa, Guttorm et al. 
2000; Kiningham, Xu et al. 2001; Konopka, Kubala et al. 2008; Traore, Sharma et al. 
2008). We have published data that supports a potential role of MnSOD in ATRA-
mediated differentiation of neuroblastoma cells (Kiningham, Cardozo et al. 2008).  
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The phorbol ester TPA, first discovered in the croton plant, was established as a 
tumor promoter by  Berenblum and Shubik (Berenblum and Shubik 1947) when applied 
to the skin of mice. The differentiation capabilities of TPA have been extensively 
examined (Weinstein, Lee et al. 1979). Additionally, among the many biological effects 
of TPA (reviewed in (Goel, Makkar et al. 2007)), as stated above, it is also a 
characteristic inducer of the MnSOD enzyme. Nevertheless, although a single dose of 
TPA stimulates MnSOD mRNA and protein in mouse skin epithelial cells (Zhao, Xue et 
al. 2001), chronic exposure has been shown to reverse this effect (reduce MnSOD) in 
transgenic mice overexpressing a MnSOD promoter-and-enhancer luciferase reporter 
gene (Dhar, Xu et al. 2007). Our work in the SK-N-SH neuroblastoma cell line suggests 
an up-regulation of MnSOD activity via NF-κB activation (Kiningham, Cardozo et al. 
2008). Supporting studies by Kiningham et al. established TPA-induction of MnSOD 
through NF-κB signaling in SV40-transformed human lung fibroblasts (Kiningham, Xu et 
al. 2001). As it is well known that NF-κB is a target transcription factor for increased 
ROS, (Kabe, Ando et al. 2005) (and reviewed in (Hsu, Young et al. 2000)), our research 
is designed to investigate which, if any, ROS are integral to influence the differentiation 
status of the SK-N-SH neuroblastoma cells. Several groups have demonstrated ROS-
dependent signaling such as in TPA-treated monocytic leukemia cells (Traore, Trush et 
al. 2005) and phagocytic cells (Zor, Ferber et al. 1993). However, such a role for ROS in 
TPA-mediated neuroblastoma differentiation has not been elucidated. In either 
application – treatment with TPA, retinoids, or growth factors – there are key questions 
remaining. Is ROS generation or MnSOD important in the process of differentiation? In 
addition, are ROS essential for the upregulation of MnSOD to influence differentiation in 
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neuroblastoma cells? Manganese SOD may act by providing a more reduced 
environment, protecting the mitochondria from oxidative damage and ensuring sufficient 
ATP production for differentiation. In addition, MnSOD may influence the intracellular 
redox state via the removal of O2
• and the production of H2O2; thereby altering signaling 
cascades.  
Our previous publication demonstrates a significant increase in MnSOD protein 
in ATRA-treated SK-N-SH cells (Kiningham, Cardozo et al. 2008), suggesting that these 
cells respond to ATRA by increasing ROS. Mitochondria are one of the major sources of 
ROS, in particular O2
•; and MnSOD is a mitochondrial enzyme up-regulated in response 
to O2
• that catalyzes its conversion to hydrogen peroxide (H2O2) and molecular oxygen 
(O2) (Buettner 2011). In the presence of retinoids, leukocytes characteristically produce 
ROS, in particular O2
•, which is correlated with their differentiation (Yen and Albright 
1984; Chomienne, Ballerini et al. 1990). Moreover, Kikuchi et al. suggest ATRA-
mediated differentiation of human monoblastic leukemia cells by signaling via O2
• 
generation (Kikuchi, Kuribayashi et al. 2010). Recent data supports a role for O2
• to 
mediate differentiation of the SH-SY-5Y cells (a subclone of SK-N-SH) by activating the 
protein kinase C (PKC) signaling cascade (Nitti, Furfaro et al. 2010). Furthermore, TPA-
induction of MnSOD mRNA is suggested to be mediated through activation of PKC- 
and -dependent signaling pathways in human lung carcinoma cells (Chung, Kim et al. 
2011). Taken together, these studies suggest that ROS and MnSOD could also have a 
role in the differentiation of neuroblastoma cells.   
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CELLULAR MODEL 
 There are numerous neuroblastoma cell types grown in culture; however each line 
has distinctive characteristics including the gender/age of patient, primary/ metastatic 
site of tumor, responsiveness to retinoid or chemotherapeutic treatments, MYCN 
amplification, the stage of the disease in which they were isolated, etc. Although the 
common effect of retinoids is to induce differentiation, there are a number of 
neuroblastoma cell lines that undergo apoptosis when treated with either natural or 
synthetic retinoids. (reviewed in (Thiele 1998)). An in vitro model of neuroblastoma, the 
SK-N-SH cell line was derived from a metastasis to the bone marrow occurring in a 
hyperdiploid female patient with stage IV disease (Biedler, Helson et al. 1973). This 
parental line is composed of three cell types: sympatheoadrenal neuroblasts (N-type), 
substrate-adherent non-neuronal (S-type), and intermediate (I-type) cells (Ross, Biedler 
et al. 2003). Unlike many neuroblastoma cell lines, SK-N-SH cells possess both tyrosine 
hydroxylase and dopamine-β-hydroxylase activity, allowing them to both synthesize 
dopamine and metabolize it into norepinephrine (reviewed in (Thiele 1998)). In contrast 
to the commonly used IMR-32 cell line, SK-N-SH cells do not possess MYCN gene 
amplification, which is evidently responsible for increased GSH biosynthesis and 
resistance to oxidative stress (Veas-Perez de Tudela, Delgado-Esteban et al. 2010). 
Future work comparing these two genetically different neuroblastoma subtypes and 
their response to ATRA may elucidate if ROS/ antioxidant modifications are either 
retinoid- or cell type-specific. Additionally, it is well established as a model to study 
retinoid-induced differentiation and is also advantageous by virtue of being a 
heterogenous culture, which more closely mimics in vivo conditions. Characterization by 
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Sidell et al. demonstrated retinoid-induced contact- and growth-inhibition, and that 
neurite extension formation is commonly associated with a decreased malignant 
phenotype (Sidell, Altman et al. 1983). We confirm these historical observations by 
identifying early neuronal differentiation markers (i.e. N-methyl-D-aspartate, 
neurofilament M) whose expression increase concurrent with growth rate suppression in 
the presence of ATRA. Our laboratory was also the first to identify an upregulation of 
the manganese superoxide dismutase (MnSOD) enzyme in this cell type during ATRA-
mediated differentiation (Kiningham, Cardozo et al. 2008). Although MnSOD is 
implicated in many models to be essential for differentiation (St Clair, Oberley et al. 
1994; Zhao, Kiningham et al. 2001; Erlejman and Oteiza 2002), its importance is not 
known in the SK-N-SH cells. In addition, we have investigated the role of ROS in this 
model in consideration of the antioxidant response by MnSOD. 
SCOPE AND HYPOTHESIS OF RESEARCH 
In order to enhance the effectiveness of ATRA in the treatment of 
neuroblastoma, a better understanding of specific signaling pathways involved in its use 
is needed. We hypothesize that ROS and/ or MnSOD play an important signaling role in 
mediating differentiation of SK-N-SH neuroblastoma cells induced by ATRA treatment.  
In particular, the current studies focus on the ability of NAC to augment ATRA’s effects 
(Chapter 2) and the importance of MnSOD in the differentiation of the SK-N-SH 
neuroblastoma cell line (Chapter 3). Chapter 4 includes supplemental data that explores 
the apoptotic fate of the SK-N-SH cells by reducing MnSOD activity. Chapter 5 briefly 
summarizes the data collected as a whole and propose future avenues for research. 
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ABSTRACT 
Background: Tumor recurrence for children with high-risk neuroblastoma is an 
unfortunate but real complication. Under such circumstances, retinoids have been used 
successfully to stimulate differentiation of neuroblastoma and slow proliferation; 
however, long-term patient survival is still poor. We propose that N-acetyl-L-cysteine 
(NAC), a pharmacologically relevant antioxidant, enhances the effectiveness of all-trans 
retinoic acid (ATRA) to differentiate a well-established in vitro model of neuroblastoma. 
The aim of this study was to provide evidence demonstrating that supplementation of 
retinoid therapy could translate into improved treatment for neuroblastoma patients.  
Methods: We investigated the effects of ATRA, NAC, and NAC+ATRA treatment on 
differentiation markers (NMDAR1: N-methyl-D-aspartate 1, NF-M: neurofilament-M) as 
well as growth characteristics of the SK-N-SH neuroblastoma cell line. We also explored 
the influence each of these treatments had on various factors involved in the redox 
status of the cell, such as superoxide (O2
•; MitoSOX) and glutathione (GSH). Activity of 
the retinoic acid response element (RARE) and expression of the retinoic acid receptor 
(RAR)-targeted protein, CRABP-II, were also examined.   
Results: ATRA treatment resulted in an early induction of MitoSOX fluorescence and a 
reduction of GSH, which is demonstrated for the first time in the neuroblastoma model. 
Increases in NMDAR1 and NF-M expression followed these redox changes. In contrast 
to many studies in other tumor cells, supplementation with NAC enhanced these 
differentiation markers and significantly reduced cellular proliferation in comparison to 
treatment with ATRA alone. Although preventing ATRA-mediated decreases in GSH, 
NAC did not reduce MitoSOX fluorescence. Furthermore, NAC enhanced ATRA-
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mediated activity of a RARE reporter gene and expression of a RAR target protein, 
cellular retinol binding protein II (CRABP-II).  
Conclusions:  We document NAC’s potential to enhance the ability of retinoids to 
stimulate neuroblastoma differentiation. Because NAC has proven to be successful and 
safe for use in conditions such as acetaminophen toxicity, the current study holds 
significant clinical impact. Acceleration of the differentiation process and retardation of 
tumor progression could be a great benefit to the survival of patients with 
neuroblastoma. Future studies must address the success of this combination therapy in 
other neuroblastoma lines and, eventually, an animal model of neuroblastoma.  
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BACKGROUND 
Neuroblastoma is the most common extracranial solid tumor in childhood, 
representing 7-10% of all pediatric cancers (Brodeur and Castleberry 1993). 
Unfortunately, 70% of neuroblastoma cases are not diagnosed until after tumors have 
already metastasized to distant sites . For high-risk neuroblastoma patients who 
experience recurring tumors after primary surgical resection, radiation, and/ or 
chemotherapy, clinicians have utilized differentiation therapy with retinoids as a 
promising treatment (Reynolds, Matthay et al. 2003). 13-cis retinoic acid (13-cis RA) is 
currently used to treat neuroblastoma; however, all-trans retinoic acid (ATRA) is the 
main signaling retinoid in vivo and one of the most potent inducers of differentiation for 
human neuroblastoma in vitro (Sidell, Altman et al. 1983). Anti-proliferative capabilities 
are suggested to be due to isomerization of the “cis” isoform to the “trans” form in 
human neuroblastoma cells (Veal, Errington et al. 2002). Therefore, the current study 
focuses on the biological effects of ATRA to induce differentiation of the SK-N-SH 
neuroblastoma cells. 
Although much work to date has focused on retinoid-mediated gene regulation 
through the nuclear retinoic acid receptors (RARs); there are reports to suggest some 
effects to develop independently of the RAR. Examples include nuclear accumulation of 
the tumor suppressor p27 upon ATRA-mediated differentiation of neuroblastoma 
(Wainwright, Lasorella et al. 2001), and retinoic acid activation of mitogen activated 
protein kinases (MAPKs) in HL60 human myeloblastic leukemia cells (Yen, Roberson et 
al. 1998). Any action of retinoids can be the result of activation of both pathways. 
Several studies have demonstrated that retinoids mediate their effects via the 
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generation of reactive oxygen species (ROS). In PC12 cells, a model system for primary 
neurons, retinol treatment increases ROS, and superoxide anion (O2
•) generation via 
xanthine/ xanthine oxidase induced neurite outgrowth (Gelain and Moreira 2008; 
Gopalakrishna, Gundimeda et al. 2008). The importance of ROS is also illustrated by 
their ability to mediate the actions of nerve growth factor (NGF) resulting in neuron 
survival, axonal regeneration, and a differentiated phenotype (Kamata, Tanaka et al. 
1996). The sum of these studies suggests that ROS play an integral part in the process 
of neuronal differentiation. 
Manipulation of ROS with thiol antioxidants such as N-acetyl-L-cysteine (NAC) is 
a common method by which to modulate the intracellular redox state. The influence of 
NAC on redox status can stem from many potential mechanisms; i.e. being a free 
radical scavenger, acting as a substrate for glutathione (GSH) synthesis, or directly 
reducing hydroperoxides and protein disulfides (Parasassi, Brunelli et al. 2010). Safely 
given clinically, NAC is most often used to treat conditions such as acetaminophen 
toxicity (Whitehouse, Wong et al. 1981) or as an adjuvant in respiratory conditions with 
excessive mucus production (De Lisle, Roach et al. 2007). Furthermore, in both normal 
human keratinocytes and human colon carcinoma models, NAC inhibits proliferation 
and promotes differentiation when used at similar concentrations (Edlundh-Rose, 
Kupershmidt et al. 2005; Gustafsson, Kupershmidt et al. 2005). Importantly for our work, 
NAC promoted retinoic acid-mediated neuronal differentiation and neuritogenesis in 
embryonic stem cells (Qian and Yang 2009). Although NAC has been used in several 
neuronal cellular models, the study reported here is the first study to confirm the 
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capacity of NAC to augment ATRA’s ability to induce differentiation of the SK-N-SH 
neuroblastoma cell line.  
METHODS 
Cell culture and treatment 
For all experiments, the human neuroblastoma cell line (SK-N-SH) obtained from the 
American Type Culture Collection (Manassas, VA) was maintained in minimal essential 
medium (MEM; Sigma, St. Louis, MO, USA) supplemented with 10% heat-inactivated 
bovine serum (Invitrogen, Carlsbad, CA, USA), 1% penicillin/streptomycin/neomycin 
(Invitrogen), 1% non-essential amino acids (Invitrogen), and 1 mM sodium pyruvate 
(Sigma-Aldrich). Dimethyl sulfoxide (DMSO), all-trans retinoic acid (ATRA) and N-
acetyl-L-cysteine (NAC) were obtained from Sigma-Aldrich. Dimethylsulfoxide (DMSO) 
(0.05%) treatment served as the control (CON). The concentration of ATRA used is 
consistent with previous reports to induce differentiation in this cell type (Sidell, Altman 
et al. 1983; Pizzi, Boroni et al. 2002). Cells receiving NAC (1 mM) were pre-treated for 
24 hrs prior to addition of ATRA, which then ensued for an additional 48 hrs. The 
concentration of NAC (1 mM) used in the current study falls within the low range of that 
found to be physiologically relevant in patients receiving NAC for acetaminophen toxicity 
(~4 mM) (Prescott, Donovan et al. 1989).   
MitoSOX fluorescence 
Cells were plated at a density of 8 x 104 cells/ cm2. At the completion of 
treatments, cells were washed with phosphate buffered saline (PBS) and incubated in 
the presence of 5 μM MitoSOX (Invitrogen) at 37°C, 5% CO2. Cells cultured in parallel 
were incubated with rotenone (1-200 µM) as a positive control for superoxide formation. 
  
 57  
 
Fluorescence was then measured (excitation at 510 nm, emission at 580 nm) at 10 and 
40 min. Data are expressed as the relative change in fluorescence between 10 and 40 
min. All absorbance values are normalized according to protein content.  
Glutathione (GSH) measurements 
 Cells were plated at a density of 3 x 104 cells/ cm2. At the completion of 
treatments, whole cell lysates were collected via scraping cells in cold PBS and 
centrifuging at 2,000 rpm for 5 min at 4°C. The resulting cell pellet was resuspended in 
potassium phosphate buffer (50 mmol/L, pH 7.8) and aliquots were saved for protein 
quantification. Sulfosalicylic acid was added to the remaining solution to achieve a final 
concentration of 5%. Samples were incubated on ice for at least 10 min, centrifuged at 
2,000 rpm for 5 min at 4°C, and supernatants were saved and stored immediately at -
80°C. Levels of reduced GSH and GSSG were distinguished by adding 2 μL of a 
mixture of 2-vinylpyridine and triethanolamine (TEA) (2:1), incubated for 30 min, and 
assayed as described by Griffith and Anderson (Griffith 1980; Anderson 1985). Data are 
represented as fold change GSH or % GSSG vs. CON per time point. 
Growth rate analysis 
 On day one, cells were plated at a density of 2 x 103 cells/ cm2. On day two, 2 
plates were counted as the 24 hr control. NAC treatment (1 mM) also began on this day. 
ATRA and NAC + ATRA treated cells received ATRA (10 μM) on day three. Two plates 
per treatment were counted and averaged each subsequent day for the duration of the 
experiment. ATRA and/ or NAC-containing culture media was replenished every 48 hrs. 
Data are represented as the average log of cell numbers vs. time (hrs).  
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Western blot analysis 
Cells were plated at a density of 1 – 3 x 104 cells/ cm2. Whole cell lysates were 
collected via scraping in cold phosphate buffered saline (PBS; 137 mM sodium chloride, 
3 mM potassium chloride, 1 mM potassium phosphate monobasic, 10 mM sodium 
phosphate dibasic; pH 7.4) and centrifuged at 1,500 rpm x 5 min at 4˚C. Pellets were 
subjected to at least one freeze-thaw cycle at -80˚C and resuspended in HALT protease 
inhibitor cocktail (Thermo Scientific, Rockford, IL, USA). Equal quantities of protein were 
used for analysis via SDS-PAGE. Proteins were transferred to nitrocellulose 
membranes and transfer efficiency was assessed by staining with 0.1% Ponceau S. 
Membranes were incubated overnight with primary antibodies neurofilament-M (NF-M) 
(1:2,000; Invitrogen), N-methyl-D-aspartate receptor 1 (NMDAR1) (1:1,000; Chemicon 
International, Temecula, CA, USA) or glyceraldehye 3-phosphate dehydrogenase 
(GAPDH) (1:50,000; Trevigen, Gaithersburg, MD, USA), followed by a horseradish 
peroxidase conjugated secondary antibody (1:3,000; Santa Cruz, Santa Cruz, CA, 
USA). Detection of antibody-protein interactions was made via the enhanced 
chemiluminescence system (Amersham Biosciences, Piscataway, NJ). All specific 
protein expression is normalized to levels of GAPDH and reported as fold change vs. 
CON (DMSO treated) or ATRA treated cells. 
RARE-luciferase activity 
Cells were plated at a density of 5 x 104 cells/ cm2. After 24 hrs cells were 
transfected with 19 µg of either an empty luciferase control vector or a RARE-luciferase 
vector using the CaPO4 method. Seven hours post transfection, cells were washed 
twice with PBS and fresh media was added. On the following day, cells were trypsinized 
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and plated in 24-well plates at a density of 7.5 x 104 cells/ cm2. At the completion of 
treatments, cells were then washed with PBS and lysed using 200 µL of Passive Lysis 
Buffer (Promega, Madison, WI, USA). Reporter assays were performed using the 
Luciferase Assay System (Promega) and TD-20/20 Luminometer (Turner Designs, 
Sunnyvale, CA, USA).  
Statistical Analysis 
All experiments were replicated at least in triplicate and values reported as mean 
±S.E.M. When comparing two means, Student’s t test was used, p<0.05. When 
comparing multiple means, the results were analyzed either by One- or Two- way 
ANOVA followed by the Student Newman-Keuls test at a 95% confidence interval. 
 
RESULTS 
NAC enhanced the expression of neuronal differentiation markers and further 
suppressed proliferation in the presence of ATRA 
In order to evaluate the process of differentiation in the SK-N-SH cell line, protein 
expression was analyzed for NMDAR1 and NF-M, common neuronal markers 
demonstrated to be prevalent in differentiating SK-N-SH cells (Gaitonde, Qi et al. 2001; 
Pizzi, Boroni et al. 2002). These function to regulate the formation of functional 
synapses (NMDAR1) (Kohr 2006) and neurite processes that are essential in protein 
trafficking and motility (NF-M) (Inagaki, Gonda et al. 1989). Within 48 hrs, there was a 
significant increase in NMDAR1 expression in ATRA treated cells in comparison to 
controls (Figure 2.1A); consistent with our previous findings (Kiningham, Cardozo et al. 
2008) and earlier than what has been previously published (Pizzi, Boroni et al. 2002). 
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Moreover, NAC pre-treatment significantly enhanced ATRA-mediated NMDAR1 
expression (2-fold) as compared to those cells receiving retinoid only. In a similar 
manner, after 48 hrs, ATRA induced a significant increase in NF-M expression (in 
accordance with previously published studies (Gaitonde, Qi et al. 2001)) that was 
enhanced 1.8-fold by pretreatment with NAC (Figure 2.1B).  
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To further elucidate the ability of NAC to enhance ATRA activity, we analyzed the 
FIGURE 2.1: ATRA-MEDIATED EXPRESSION OF NMDAR1 AND NF-M WAS ENHANCED BY NAC.  
Western Blot analysis of (A) NMDAR1 (n=7) and (B) NF-M (n=4) expression after 
treatment with ATRA (10 μM), NAC (1 mM), and NAC (1 mM) + ATRA (10 μM) for 48 
hrs. (A): *p < 0.05 vs. ATRA(+/-); (B): *p < 0.05 vs.CON(-/-), †p < 0.001 vs. CON, ‡p < 
0.05 vs. ATRA. Two way ANOVA; Student-Newman-Keuls. Results are expressed as 
fold changes vs. CON (-/-; NF-M) or ATRA (+/-; NMDAR1) + SEM. ND: non-detectable. 
A 
B 
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 To further elucidate the ability of NAC to enhance ATRA activity, we analyzed the 
growth rates of SK-N-SH cells when treated in the same manner (Figure 2.2). Statistical 
analysis was performed on lines generated between 24-96 hrs and 96-192 hrs. The SK-
N-SH cell line is comprised of a mixture of epithelial (S-type), neuronal (N-type), and 
intermediate cells (I-type); and the precipitous drop in cell number after 144 hrs likely 
represents death of S-type cells in the presence of ATRA . Prior to 96 hrs, there was no 
significant difference in the slope of lines generated from any treatment. However, after 
96 hrs, there was a significant change in growth characteristics. Cells treated with ATRA 
and NAC+ATRA demonstrated a significant reduction in growth rate as compared to 
controls (denoted by the *). The slope of the line (between 96-192 hrs) generated from 
cells receiving NAC did not significantly differ from control. Additionally, NAC+ATRA 
treatment of cells did not significantly decrease the slope of either portions of the line in 
comparison to ATRA alone. However, the combination of NAC with ATRA demonstrated 
a significant reduction in elevation in comparison to ATRA alone (denoted by the †). By 
96 hrs, cell number was already significantly decreased by combining NAC with ATRA, 
and implicates that ultimate cell number at the end of treatments was significantly 
lowered. This finding supports a role for NAC to further suppress proliferation by ATRA.  
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* 
*† 
FIGURE 2.2: ATRA AND NAC DECREASED CELL NUMBERS.  
Growth rate analysis of SK-N-SH cells after treatment with ATRA (10 μM), NAC (1 
mM), and NAC (1 mM) + ATRA (10 μM) for 24-192 hrs (n=3). Average log cell number 
+ SEM is plotted vs. time (hrs). *Slope (growth rate) between 24-96 hrs and 96-192 hrs 
is significantly different from CON. 
†
Elevation (cell number) at 96 hrs is significantly 
different from ATRA. Linear regression analysis was performed between 24-96 hrs and 
96-192 hrs to analyze both portions of the lines.  
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The effects of ATRA and NAC on redox factors O2
• and GSH 
Our previous publication demonstrates a significant increase in MnSOD protein 
in ATRA-treated SK-N-SH cells (Kiningham, Cardozo et al. 2008). This finding suggests 
that SK-N-SH cells respond to ATRA by increasing ROS. Mitochondria are one of the 
major sources of ROS, in particular O2
•; and MnSOD is a mitochondrial enzyme up-
regulated in response to O2
•, catalyzing its conversion to hydrogen peroxide (H2O2) and 
molecular oxygen (O2) (Buettner 2011). Therefore, MitoSOX, a fluorescent indicator of 
mitochondrial O2
•, was utilized to assess this ROS in the presence of ATRA. There was 
a significant increase in MitoSOX fluorescence (indicative of O2
•) as early as 24 hrs in 
ATRA-treated cells. The increase was maintained for 48 hrs (Figure 2.3A) and is 
consistent with an increase in MnSOD protein and activity after 72 hrs of ATRA 
treatment (Kiningham, Cardozo et al. 2008). There was no significant change in 
MitoSOX fluorescence in the presence of NAC alone as compared to controls. 
Additionally, the changes in MitoSOX fluorescence between ATRA alone and 
NAC+ATRA were not significantly different at either 24 or 48 hrs. Rotenone, an inhibitor 
of complex I in the mitochondrial electron transport chain, was used as a positive control 
and produced a concentration-dependent increase in MitoSOX fluorescence (1 - 200 
μM), consistent with its ability to increase O2
• formation (Figure 2.3B). 
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  FIGURE 2.3: NAC DID NOT ATTENUATE THE ATRA-MEDIATED INCREASE IN MITOSOX 
FLUORESCENCE. 
(A) MitoSOX fluorescence after treatment with ATRA (10 μM), NAC (1 mM), and 
NAC (1 mM) + ATRA (10 μM) for 24 and 48 hrs. n=7. *p < 0.05. Repeated 
measures two-way ANOVA performed per time point; Student-Newman-Keuls (ns: 
not significant). Results are expressed as relative changes in fluorescence + SEM. 
(B) Rotenone treatment produced a concentration-dependent increase in 
MitoSOX fluorescence.  
A 
B 
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Because a first line of defense against ROS is GSH, levels of this non-protein 
thiol were measured to assess its role in the cellular response to ATRA. Glutathione 
was significantly decreased by 50% in cells treated with ATRA for 24 and 48 hrs relative 
to control cells (Figure 2.4A). Treatment with NAC alone did not increase GSH versus 
controls; however, at 24 hrs, the increase in the presence of NAC+ATRA was significant 
in comparison to ATRA. Thus, at this time point there was a statistically significant 
interaction in that NAC inhibited the ability of ATRA to decrease GSH levels. Within 48 
hrs, in the presence of NAC, GSH levels returned to levels that were comparable with 
controls. Although we observed an increase in oxidized GSH (GSSG) with ATRA and 
NAC+ATRA at 48 hrs, statistically this was not significant relative to controls (Figure 
2.4B).  
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FIGURE 2.4: NAC INHIBITED ATRA-MEDIATED DECREASE OF GLUTATHIONE (GSH).  
(A) Reduced GSH and (B) GSSG levels after treatment with ATRA (10 μM), NAC (1 
mM), and NAC (1 mM) + ATRA (10 μM) after 24 and 48 hrs. n=7. *p < 0.05. Repeated 
measures two-way ANOVA performed per time point; Student-Newman-Keuls (ns: not 
significant). Results are expressed as reduced GSH (nmol/ mg protein) + SEM or % 
GSSG (fold change vs. CON) + SEM. 
A 
B 
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NAC enhanced ATRA-mediated activity of the RARE and CRABP-II expression 
Next we investigated whether NAC enhances ATRA-stimulated gene expression 
by using a DR-5 (direct repeats separated by 5 base pairs) retinoic acid response 
element (RARE) cloned into a luciferase reporter plasmid. ATRA treatment of 
transfected cells significantly increased luciferase activity 13-fold as compared to 
controls (Figure 2.5). Furthermore, we observed a significant enhancement (1.2 fold)  of 
luciferase activity in cells receiving both NAC and ATRA relative to cells treated with 
retinoid alone. Treatment with ATRA, but not NAC, significantly increased luciferase 
activity relative to control cells transfected with the empty vector. These data are 
consistent with previously reported findings in breast cancer cells (Kogai, Kanamoto et 
al. 2003). To confirm these results, cells were analyzed for the expression of cellular 
retinoic acid binding protein II (CRABP-II), a well-established target of retinoids and 
known to be up-regulated through activation of an RARE in its gene promoter (Kato, 
Blaner et al. 1985; Astrom, Tavakkol et al. 1991). This protein was undetectable in both 
control and NAC treated cells. Treatment with NAC+ATRA resulted in a significant 
increase (1.5-fold) in CRABP-II expression versus ATRA alone (Figure 2.6). 
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FIGURE 2.5: NAC ENHANCED ATRA-MEDIATED ACTIVITY OF THE RARE.  
Luciferase activity of cells transfected with an empty vector (Control □) or one 
containing the RARE (■) and treated with ATRA (10 μM), NAC (1 mM), or NAC (1 mM) 
+ ATRA (10 μM). *p < 0.05 vs. CON(-/-); 
†
p < 0.001 vs. CON(-/-); 
‡
p < 0.05 vs. ATRA. 
n=4. One-way ANOVA; Student-Newman-Keuls. Results are expressed as fold 
changes vs. CON(-/-) + SEM. 
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FIGURE 2.6: NAC ENHANCED EXPRESSION OF CRABP-II IN THE PRESENCE OF ATRA.  
CRABP-II protein expression of cells treated with ATRA (10 μM), NAC (1 mM), or  
NAC (1 mM) + ATRA (10 μM). *p < 0.05 vs. ATRA(+/-). n=5. T-test. Results are 
expressed as fold changes vs. ATRA (+/-) + SEM. ND: non-detectable. 
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DISCUSSION 
This study establishes for the first time that NAC enhances ATRA induction of 
neuronal differentiation markers in neuroblastoma. Previous studies, using the same 
concentration of NAC, demonstrated the ability of NAC to enhance ATRA-induced 
neuritogenesis in embryonic stem cells (ESCs) (Qian and Yang 2009). However, there 
are other studies to suggest that NAC attenuates the process of differentiation of cancer 
cells (Suzukawa, Miura et al. 2000; Konopka, Kubala et al. 2008). Konopka et al. used 
high concentrations of NAC (5 mM) and a low concentration of retinoic acid (0.2 μM) to 
show that NAC attenuated retinoic acid-induced differentiation of P19 embryonal 
carcinoma cells (Konopka, Kubala et al. 2008). These disparities in concentrations 
relative to what we used in the study reported here may significantly affect overall levels 
of ROS; leading to a different outcome on ATRA’s differentiation-inducing ability. 
Furthermore, because the relative redox status is dependent on a balance of ROS and 
antioxidants, it is possible that basal levels of antioxidants are different in the P19 cell 
type versus that of a non-embryonic lineage (SK-N-SH). Given at higher concentrations 
(5-20 mM), NAC caused delays in the progression of G1 to S phase and a reduction in 
cyclin D1 levels when administered to mouse fibroblasts (Menon, Sarsour et al. 2007). 
Our data demonstrates an attenuation of cell growth using a more physiologically 
relevant concentration. Thus, in addition to its already well-established therapeutic 
benefits, there is evidence NAC can also be used as an anti-proliferative agent. When 
comparing the effects of NAC in cancer models, differences in cell type, concentration 
of antioxidant, time of treatment, and differentiation markers must be considered.  
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Previous reports demonstrate that retinoids enhance the generation of ROS (Yen 
and Albright 1984; Chomienne, Ballerini et al. 1990; Konopka, Kubala et al. 2008; 
Kikuchi, Kuribayashi et al. 2010; Nitti, Furfaro et al. 2010), and our data also show 
ATRA-induced early alterations in redox status, indicated by increased MitoSOX 
fluorescence (implicating O2
• generation) and decreased GSH levels. It is well 
established that leukocytes characteristically produce O2
• in the presence of retinoids, 
which is correlated with their differentiation (Yen and Albright 1984; Chomienne, 
Ballerini et al. 1990). Furthermore, differentiation of the SH-SY-5Y cells is reportedly 
facilitated by generation of O2
•, which activates the protein kinase C (PKC) signaling 
cascade (Nitti, Furfaro et al. 2010). Nonetheless, it remains to be determined if and 
what role O2
• plays in the differentiation of SK-N-SH cells by ATRA. Furthermore, 
additional studies must address the mechanism of ATRA-induced O2
•. 
  In addition to the production of O2
•, we also made the novel finding in a model of 
neuroblastoma differentiation that ATRA caused a significant reduction of GSH levels. 
This result is supported in studies performed in IMR-32 neuroblastoma cells where 
dibutyryl cAMP and 5-bromo-deoxyuridine-mediated differentiation resulted in lower 
total GSH levels and a higher ratio of oxidized vs. the reduced form (Erlejman and 
Oteiza 2002). Carystinos et al. also demonstrated that ATRA decreased GSH in the 
IMR-32 cells. Although ATRA enhanced cAMP-mediated decreases in GSH, there was 
no significant reduction when ATRA was used as a single reagent (Carystinos, Alaoui-
Jamali et al. 2001). This observation could be explained by MYCN gene amplification, 
which is reportedly responsible for increased GSH biosynthesis (in comparison to 
neuroblastoma subtypes without MYCN amplification) and resistance to oxidative stress 
  
 73  
 
(Veas-Perez de Tudela, Delgado-Esteban et al. 2010). Therefore, in the case of IMR-32 
cells, ATRA treatment may have been insufficient to overcome higher basal levels of 
GSH. Alternatively, administration of the synthetic retinoid, 4HPR (fenretinide) increased 
GSH and ROS in MYCN amplified neuroblastoma cell lines (IMR-32, SJ8, SJNB10) 
(Cuperus, van Kuilenburg et al. 2011). In contrast to our work, this latter study used cell 
models to demonstrate retinoid-induced cytotoxicity of neuroblastoma; and 4HPR 
stimulated very large increases in ROS. Absolute GSH depletion or extremely high ROS 
generation is usually associated more with cell death, and may be mediated through 
different signaling cascades than those involved in the differentiation process 
(Anderson, Tsai et al. 1999; Wu, DiPietrantonio et al. 2001; Filomeni, Piccirillo et al. 
2012). Given the information above, a comparative analysis between the SK-N-SH and 
MYCN amplified cells (i.e. IMR-32) should be performed using equimolar concentrations 
of ATRA or 4HPR to assess if ROS/ antioxidant modifications are either retinoid- or cell 
type-specific.  
Transient decreases in GSH levels reportedly enhanced the differentiation of 
HL60 leukemia cells (Krance, Keng et al. 2010), which may explain ATRA’s effects in 
the SK-N-SH’s. Additionally, many studies implicate GSH as an essential mediator of 
cellular proliferation (Reddy, Kleeberger et al. 2007a; Reddy, Kleeberger et al. 2007b). 
Supplementation with GSH rescued the proliferative defects in Nrf2 (nuclear factor 
erythroid-derived 2) deficient lung epithelial cells (Reddy, Kleeberger et al. 2007) and 
depletion by use of buthionine sulfoximine (BSO) enhanced oxidative stress and 
decreased proliferation of alveolar epithelial cells (Reddy, Kleeberger et al. 2008). 
Several groups have also investigated the role of Nrf2, which is a master regulator of 
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GSH-biosynthesizing enzymes. Retinoic acid upregulates the Nrf2 antioxidant response 
system within 24 hrs in the SH-SY-5Y cells (Zhao, Wu et al. 2009). Although the authors 
demonstrated increased expression of the Nrf2 target, NAD(P)H quinone reductase 
(NQO1), it was not established whether GSH levels were also increased. Wang et al. 
demonstrated a direct RARmediated effect by showing that ATRA caused 
suppression of Nrf2 activity by liganded RAR, inhibiting recruitment of Nrf2 to the ARE 
in MCF-7 breast cancer cells (Wang, Hayes et al. 2007). Future work should focus on 
whether the same mechanism is responsible for the ATRA-mediated reduction in GSH 
that we documented in the SK-N-SH neuroblastoma cells. 
Despite NAC’s inability to attenuate ATRA-mediated induction of MitoSOX 
fluorescence at either 24 or 48 hrs, NAC blocked ATRA-reduction of GSH levels at 24 
hrs (Figs. 3 and 4). It is possible that transport of cytosolic GSH to the mitochondria was 
not substantial enough to reduce levels of ROS (as measured by MitoSOX). 
Additionally, cells were pretreated with NAC for 24 hrs, which may explain the ability of 
NAC to prevent ATRA-reduction of GSH. In a model of acute lung injury NAC 
significantly elevated Nrf2 expression (Ji, Liu et al. 2010), suggesting that this thiol can 
increase GSH levels transcriptionally and not just by being a precursor for GSH 
synthesis. Because ATRA is redox sensitive (Adamson 1996), the maintenance of GSH 
with NAC pretreatment might also contribute to preventing oxidation of this retinoid, and 
therefore increase its bioavailability for binding to the RAR. Future work is needed to 
explore 1) the mechanism of GSH regulation by ATRA and NAC and 2) if there is a role 
of Nrf2 in this neuroblastoma cell line.  
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Our previous work established that NF-κB is integral in promoting NMDAR1 
upregulation by ATRA (Kiningham, Cardozo et al. 2008). Liu et al. demonstrated that 
NAC induces DNA-binding activity of NF-κB and phosphorylation of the p65 subunit 
(Liu, Yoshida et al. 2008). Our finding that NAC enhanced ATRA-mediated NMDAR1 
expression might be explained by enhanced NF- κB activation and acceleration of the 
differentiation process. Studies also report that the phosphorylated NF-κB p65 subunit 
repressed transcriptional activity of Nrf2 in HepG2 liver carcinoma cells (Liu, Qu et al. 
2008). Therefore, Nrf2 repression by NF-κB may explain the ability of ATRA to decrease 
GSH. However, it remains to be determined if NF-κB plays a role in reducing GSH 
levels in the SK-N-SH cells. Our current study also shows that NAC increased NF-M in 
the absence of ATRA. The stability and structure of intermediate filament proteins such 
as NF-M are susceptible to oxidative stress (Gelinas, Chapados et al. 2000). NAC may 
alter redox status (perhaps via a GSH-independent mechanism) in the vicinity of this 
intermediate filament protein such that it promotes the polymerization of NF-M and 
inhibits its degradation.   
The ability of NAC to enhance ATRA-mediated transcriptional activity of the 
RARE and CRABP-II expression suggests that there may be a RAR component NAC 
augmenting both NMDAR1 and NF-M protein levels. Again, NAC may prevent ATRA 
oxidation and thereby increase its bioavailability to bind to the RAR. In addition, despite 
the activation of the classic “sensor” transcription factors (i.e. NF-κB, Nrf2) and 
antioxidants (i.e. MnSOD) in the event of oxidative stress, it is well established that a 
more reduced environment is more permissible for transcription factor binding (Sun and 
Oberley 1996; Brigelius-Flohe and Flohe 2011). Thus, NAC may act to attenuate an 
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initial increase in ROS by ATRA, maintain the nuclear environment in a reduced state, 
and therefore allow ATRA-mediated RAR-RXR binding and upregulation of 
differentiation markers NMDAR1 and NF-M. Supporting studies by Demary et al. 
demonstrate in melanoma cells that the RARE is redox sensitive, where increased 
oxidative stress interferes with the ability of the RAR-RXR heterodimer to bind (Demary, 
Wong et al. 2001). Treatment with NAC resensitized retinoic acid-resistant A375 
melanoma cells and restored RARE activity. The authors suggest that RAR activity is 
likely the result of epigenetic regulation, such as that imparted by a change in redox 
status.   
Parallel studies in the SH-SY-5Y cell line have rendered similar results on ATRA-
mediated differentiation. However, as discussed briefly above, 13-cis RA is the current 
mode of differentiation therapy for neuroblastoma. Therefore, future studies will address 
combination treatment with NAC and 13-cis RA, to conclude that the effects observed in 
both the SK-N-SH and SH-SY-5Y cell lines are due to 13-cis isomerization to ATRA. We 
propose that future work also address the ability of NAC to accelerate ATRA-mediated 
differentiation of non-MYCN amplified neuroblastoma models. A comparative analysis 
between these two genetically different cell types will advance the field and elucidate 
effects specific to either NAC or ROS in the presence and absence of MYC.  
CONCLUSIONS 
In order to enhance the effectiveness of ATRA in the treatment of 
neuroblastoma, we need a better understanding of its specific signaling pathways. 
Based on the results presented here, we propose a hypothetical model (Figure 2.7) 
illustrating how ATRA promotes neuronal differentiation and how NAC might enhance 
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this process. In particular, our study focuses on the role of ROS in ATRA-mediated 
differentiation, and suggests that its generation may attenuate the effectiveness of this 
retinoid. Drug resistance is a common problem in retinoid therapy and modulation of 
ROS generation by antioxidants might be a means to alleviate this problem. 
Furthermore, if neuroblastoma is diagnosed early clinicians may delay treatment to see 
if the tumor will spontaneously differentiate. In this situation, use of the non-toxic 
antioxidant NAC might have advantages by attenuating cancer cell growth, therefore 
slowing tumor progression. Our work combined with the documented beneficial and 
safe uses of NAC in the clinic, suggest that a thiol supplement may be valuable when 
administered in combination with retinoids to improve neuroblastoma differentiation 
therapy.  
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FIGURE 2.7: SCHEMATIC MODEL OF ATRA-MEDIATED DIFFERENTIATION. 
ATRA is proposed to upregulate differentiation markers (NF-M: neurofilament M; 
NMDAR1: N-methyl-D-aspartate receptor 1) in a variety of ways. It is known that ATRA 
increases RARE activity, ROS, and NF-κB activity. ROS have been shown to modulate 
the activity of both the RARE and NF-κB. Increased RARE activity can also increase 
NF-κB activity. Our previous reports demonstrate that NF-κB modulates expression of 
both MnSOD and NMDAR1. Its role in NF-M upregulation has not been determined. 
Our current report supports a role for NAC to further suppress proliferation and 
enhance upregulation of differentiation markers (NF-M and NMDAR1) in the presence 
of ATRA. NAC may also prevent the oxidation (ox) of ATRA and increase its 
bioavailability. We also demonstrate the ability of NAC to enhance ATRA-mediated 
activity of the RARE and the target gene, CRABP-II. Unknown are the roles that the 
RARE plays in the upregulation of MnSOD, NF-M, and NMDAR1. 
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ABSTRACT 
Neuroblastoma is the most common extracranial solid tumor in childhood; and 
unfortunately, patients in stage IV have a high propensity for tumor recurrence. 
Therefore, retinoid therapy has been utilized as a means to induce differentiation of 
tumor cells and to avoid/ lessen relapse. Nevertheless, the drawback of long-term 
retinoid treatment is that patients acquire chemoresistance. All-trans retinoic acid 
(ATRA) is the most potent inducer of differentiation of neuroblastoma cells in vitro. In 
support of our previous publication identifying ATRA-induction of manganese 
superoxide dismutase (MnSOD) in the SK-N-SH cells, we currently demonstrate 
increased ROS levels (superoxide anion, O2
•; hydrogen peroxide, H2O2) associated with 
upregulation of this essential antioxidant enzyme. In addition, we clearly identify 
MnSOD-mediated generation of H2O2 and no subsequent upregulation of antioxidants 
(glutathione peroxidase (GPx), catalase) to degrade this H2O2. Furthermore, the 
differentiation marker neurofilament M (NF-M) was attenuated by either reducing 
MnSOD activity or treating the cells with PegCAT. Taken together, these data suggest a 
role for H2O2 to promote the process of differentiation. Interestingly, we show stimulation 
of NF-M (48 hrs) prior to ATRA-mediated MnSOD induction. However, reducing MnSOD 
activity with siRNA resulted in an enhancement of NF-M expression at this early time 
point. Therefore, these data suggest that although MnSOD may not be essential for the 
initiation of differentiation, baseline levels influence at least one marker. This study 
validates the importance of ROS and MnSOD, and provides a close analysis of these 
factors during the early process of neuronal differentiation. By elucidating the roles each 
of these plays, we can tailor retinoid therapy to improve patient outcome. 
  
 86  
 
INTRODUCTION 
Children diagnosed with high-risk neuroblastoma are highly susceptible to 
recurrent tumors, even after initial treatments such as surgery, radiation and/ or 
chemotherapy. Retinoids are a successful therapeutic option for these patients. All-trans 
retinoic acid (ATRA; tretinoin) and 13-cis-retinoic acid (13-cis RA; isotretinoin), 
metabolites of Vitamin A, not only stimulate differentiation (Reynolds and Lemons 
2001), but also inhibit cellular proliferation, induce apoptosis (Altucci and Gronemeyer 
2001), and promote cell cycle arrest (Donato, Suh et al. 2007). Although 13-cis RA is 
currently administered clinically, ATRA is the ultimate metabolite in vivo and one of the 
most potent differentiation inducers for human neuroblastoma in vitro (Sidell, Altman et 
al. 1983). The “cis” isoform likely has effects independent of ATRA; however, anti-
proliferative capabilities are suggested to be due to isomerization to the “trans” form in 
human neuroblastoma cells (Veal, Errington et al. 2002). Despite its ability to 
differentiate cancer cells, the drawback of long-term retinoid treatment is that patients 
acquire resistance to chemotherapeutic drugs such as adriamycin and cisplatin 
(Lasorella, Iavarone et al. 1995; Freemantle, Spinella et al. 2003). Nonetheless, 
retinoids are a much safer, less toxic alternative. Further characterizing retinoids’ 
influence on particular signaling pathways is necessary to understand both its benefits 
and limitations.  
Many studies demonstrate that retinoids generate reactive oxygen species 
(ROS) and modulate antioxidant enzymes (Mantymaa, Guttorm et al. 2000; Gelain and 
Moreira 2008; Konopka, Kubala et al. 2008; Nitti, Furfaro et al. 2010). Reactive oxygen 
species are produced naturally in the cell primarily by means of the electron transport 
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chain. About 1-3% of oxygen consumed by the body is converted into ROS; three of the 
most prominent being superoxide anion (O2
•), hydrogen peroxide (H2O2) and hydroxyl 
radical (•OH) (Sohal and Weindruch 1996). Therefore, cells have developed a means to 
limit excess accumulation of ROS. Such a response involves the presence of 
antioxidants, some of which are enzymatic (superoxide dismutases, catalase, and 
glutathione peroxidase) and others which are not (glutathione, thiols, and vitamins) 
(Chance, Sies et al. 1979). We have previously reported a time-dependent ATRA-
mediated increase in manganese superoxide dismutase (MnSOD) mRNA, protein and 
activity in the SK-N-SH cells (Kiningham, Cardozo et al. 2008); and the current study 
identifies a rise in ROS levels that likely initiates this adaptive response by MnSOD. The 
aims of this study are to determine if ROS/ and or MnSOD play a role in ATRA-
mediated differentiation.  
In PC12 cells, generation of O2
• via xanthine/ xanthine oxidase induces neurite 
outgrowth, which is characteristic of differentiation of this and other neuronal cell types 
(Gopalakrishna, Gundimeda et al. 2008). Kamata and others suggest that ROS (i.e. 
H2O2) mediate the actions of nerve growth factor (NGF) to promote neuron survival and 
axonal regeneration also in PC12 cells (Kamata, Tanaka et al. 1996; Suzukawa, Miura 
et al. 2000). We now provide a time-course analysis of ROS generation that 
corresponds with antioxidant expression in differentiating SK-N-SH neuroblastoma cells. 
Because the overall redox status of a cell results as a combination of these two factors, 
investigating the relative contributions of each allows us to identify targets of regulation 
in order to improve retinoid therapy.  
  
 88  
 
MnSOD is a mitochondrial enzyme upregulated in the presence of O2
• (Privalle 
and Fridovich 1987; Culotta, Yang et al. 2006), and has been shown by Fridovich and 
others to be necessary for survival in all oxygen-metabolizing cells (McCord, Keele et al. 
1971). Homozygous MnSOD null mice cannot survive and die within the first 10 days of 
life due to dilated cardiomyopathy and neurodegeneration (Li, Huang et al. 1995; 
Lebovitz, Zhang et al. 1996). This essential antioxidant enzyme not only protects 
against ROS accumulation, but is important in the process of differentiation (St Clair, 
Oberley et al. 1994; Cassano, Agnese et al. 2010). Transfection of human MnSOD 
cDNA into mouse 10T1/2 embryonic cells enhanced 5-azacytidine mediated 
differentiation (St Clair, Oberley et al. 1994). Important for our study, differentiation of 
IMR-32 neuroblastoma cells resulted in an increase in MnSOD activity, which correlated 
with an increase in ROS (Erlejman and Oteiza 2002). Nonetheless, to our knowledge, 
no one has determined whether MnSOD is essential in ATRA mediated differentiation of 
the SK-N-SH neuroblastoma model. Additionally, these early time points have not been 
investigated. In the current study, we demonstrate a significant increase in 
neurofilament M (NF-M) protein prior to ATRA-induction of MnSOD activity (which 
occurs at 72 hrs). NF-M is expressed in neurite processes and is essential in protein 
trafficking and motility (Inagaki and Shibata 1989). However, at 48 hrs, reducing 
MnSOD with siRNA enhanced NF-M expression in the presence of ATRA. Together, 
our data suggest that MnSOD may not be essential to initiate differentiation, yet its 
activity may attenuate expression of at least one neuronal marker, NF-M. 
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METHODS 
Cell culture and treatment 
For all experiments, the human neuroblastoma cell line (SK-N-SH) obtained from 
the American Type Culture Collection (Manassas, VA) was maintained in minimal 
essential medium (MEM; Sigma, St. Louis, MO) supplemented with 10% heat-
inactivated bovine serum (Invitrogen, Carlsbad, CA), 1% penicillin/ streptomycin/ 
neomycin (Invitrogen), 1% non-essential amino acids (Invitrogen), and 1 mM sodium 
pyruvate (Sigma-Aldrich). Cells were grown at 37°C in a humidified atmosphere 
containing 5% CO2. Dimethyl sulfoxide (DMSO) and all-trans retinoic acid (ATRA) were 
obtained from Sigma-Aldrich. DMSO (0.05%) treatment served as the control and 
followed the same regimen as ATRA treatment (10 μM). The concentration of ATRA 
used is consistent with previous reports to induce differentiation in this cell type (Sidell, 
Altman et al. 1983; Pizzi, Boroni et al. 2002). Representative pictures were obtained by 
use of an Olympus CKX41 Inverted Microscope with Camera and MicroSuite V Imaging 
software (10X magnification). 
Growth rate analysis 
On day one, cells were plated at a density of 2 x 103 cells/ cm2. On day two, 2 
plates were counted as the 24 hr control. NAC treatment (1 mM) also began on this day. 
ATRA and NAC + ATRA treated cells received ATRA (10 μM) on day three. Two plates 
per treatment were counted and averaged each subsequent day for the duration of the 
experiment. ATRA-containing culture media was replenished every 48 hrs. The data are 
represented as the average log of cell numbers vs. time (hrs). 
  
 90  
 
Western blot analysis 
 Cells were plated 24 hrs prior to initiating treatments at a density of 1 – 5 x 104 
cells/ cm2. Whole cell lysates were collected via scraping in cold phosphate buffered 
saline (PBS; 137 mM sodium chloride, 3 mM potassium chloride, 1 mM potassium 
phosphate monobasic, 10 mM sodium phosphate dibasic; pH 7.4) and centrifuged at 1 
500 rpm x 5 min at 4˚C. Pellets were subjected to at least one freeze-thaw cycle at -
80˚C and resuspended in HALT protease inhibitor cocktail (Thermo Scientific, Rockford, 
IL) to be analyzed via SDS-PAGE. Proteins were transferred to nitrocellulose 
membranes and transfer efficiency was assessed by staining with 0.1% Ponceau S. 
Membranes were incubated overnight with primary antibodies neurofilament-M (1:2 000; 
Invitrogen, Carlsbad, CA), or glyceraldehye 3-phosphate dehydrogenase (GAPDH) 
(1:50 000; Trevigen, Gaithersburg, MD), followed by a horseradish peroxidase 
conjugated secondary antibody (1:3 000; Santa Cruz, Santa Cruz, CA). Detection of 
antibody-protein interactions were made via the enhanced chemiluminescence system 
(Amersham Biosciences, Piscataway, NJ). All specific protein expression was 
normalized to levels of GAPDH and reported as fold vs. control (CON: DMSO treated 
cells). 
5(and-6)-chloromethyl-2’,7’-dichlorodihydro-fluorescein diacetate (DCF) and 
MitoSOX fluorescence 
 Oxidant generation was assessed by monitoring the formation of ROS using 
5(and-6)-chloromethyl-2’,7’-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-
H2DCFDA, “DCF”, Invitrogen) and MitoSOX™ Red mitochondrial superoxide indicator 
(Invitrogen). For DCF assays, SK-N-SH cells were plated 48 hrs before initiation of 
treatments at a density of 5 x 104 cells/ cm2. At the completion of treatments (or siRNA 
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transfections), cells were washed 1X with serum free MEM (SF-MEM) and incubated in 
the presence of 2.5 µM CM-H2DCFDA in SF-MEM for 5 min at 37°C, 5% CO2. Cells 
cultured in parallel were incubated with 0.1-10 µM H2O2 after DCF incubation as a 
positive control. All cells were then washed 1X with PBS, trypsinized, and collected for 
FACS analysis (excitation at 493 nm, emission at 525 nm). Carboxy-DCFDA (Molecular 
Probes, Eugene, OR) (2.5 µM) is an oxidation insensitive dye that was used as a control 
for changes in uptake, ester cleavage, and efflux so that changes in fluorescence seen 
with the oxidation-sensitive dye could be directly attributed to changes in pro-oxidant 
production. Median fluorescence intensity of 10,000 cells was analyzed in each sample. 
For MitoSOX assays, cells were plated at a density of 8 x 104 cells/ cm2 48 hrs before 
initiation of treatments. At the completion of treatments, cells were washed with PBS 
and incubated in the presence of 5 μM MitoSOX for 10 min at 37°C, 5% CO2. Cells 
cultured in parallel were incubated with rotenone (1-200 µM) and MitoSOX (described 
above) as a positive control. Fluorescence was then measured (excitation at 510 nm, 
emission at 580 nm) at 10 and 40 min. The relative difference in fluorescence between 
10 and 40 min is expressed as the fold change of treated vs. control. All absorbance 
values were also normalized according to protein content.  
Glutathione (GSH) measurements 
 Cells were plated at a density of 3 x 104 cells/ cm2. At the completion of 
treatments, whole cell lysates were collected via scraping cells in cold PBS and 
centrifuging at 2,000 rpm for 5 min at 4°C. The resulting cell pellet was resuspended in 
potassium phosphate buffer (50 mmol/L, pH 7.8) and aliquots were taken for 
quantification of protein concentration. Sulfosalicylic acid was added to the remaining 
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solution at a concentration required to achieve a final value of 5%. Samples were 
incubated on ice for at least 10 min, centrifuged at 2,000 rpm for 5 min at 4°C, and 
supernatants were saved and stored immediately at -80°C. Levels of GSH and GSSG 
were distinguished by adding a mixture of 2-vinylpyridine and triethanolamine (TEA) 
(2:1), incubated for 30 min, and assayed as described by Griffith and Anderson (Griffith 
1980; Anderson 1985). All values were normalized according to protein content and 
reported as fold change vs. control. 
Glutathione peroxidase and catalase activity 
 Cells were plated at a density of 3 x 104 cells/ cm2. At the completion of 
treatments, whole cell lysates were collected via scraping cells in cold PBS and 
centrifuging at 2,000 rpm for 5 min at 4°C. The resulting cell pellet was stored at -80°C 
until being resuspended in potassium phosphate buffer (50 mmol/L, pH 7.8) with 
DETAPAC (1.34 mM diethylenetriaminepentaacetic acid) and 0.02% bovine serum 
albumin. For catalase activity, samples were then incubated in the presence of 0.765 
mM H2O2 and immediately analyzed spectrophotometrically for 90 sec at 240 nm. The 
change in absorbance within 60 sec was recorded to reflect catalase activity in each 
sample. Glutathione peroxidase (GPx) activity was determined according to the method 
of (Lawrence and Burk 1976). Briefly, samples were added to a solution of phosphate 
buffer (100 mM Tris/HCl pH 7.6, 5 mM EDTA, 1 mM sodium azide), reduced glutathione 
(3 mM), glutathione reductase (600 U/mL), and NADPH (0.1 mM); then incubated at 
30˚C for 5 min. The enzymatic reaction was started by adding H2O2 (final concentration 
of 1.5 mM) and evaluated by measurement of NADPH consumption at 340 nm. All 
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values were normalized according to protein content and reported as milliunits (munits)/ 
mg protein.  
MnSOD activity 
 Activity of SOD was measured in whole cell lysates using an indirect competition 
assay between SOD and the indicator compound, nitroblue tetrazolium, for superoxide 
produced by xanthine/xanthine oxidase (Spitz and Oberley 1989; Oberley, Ridnour et al. 
1989). The activity of the MnSOD isoform was measured in the presence of sodium 
cyanide, an inhibitor of copper zinc SOD. The data were normalized to protein content 
as measured by the Bradford colorimetric assay utilizing bovine serum albumin as a 
control and reported as units/ mg protein.  
SOD2 siRNA transfections 
  Small interfering RNA against the human SOD2 gene was used to silence 
expression of MnSOD. Cells were plated 24 hrs before initiation of treatments at a 
density of 3 x 104 cells/ cm2. Cells were then rinsed with serum free MEM (SF-MEM) 
prior to transfection with either ~100 nM SOD2 small interfering RNA (SOD2 siRNA) 
(ON-TARGET plus SMART pool, Dharmacon Inc, Chicago, IL) or Control siRNA (Ctrl 
siRNA) ((siCONTROL non-targeting siRNA, Dharmacon Inc, Chicago, IL) using 
Hiperfect transfection reagent (Qiagen, Valencia, CA). Transfected cells were treated 
with either vehicle or ATRA (10 μM) 24 hrs later. Following treatments, whole cell 
lysates were collected via scraping in cold PBS, and centrifuged at 1,500 rpm x 5 min at 
4˚C. Pellets were subjected to at least one freeze-thaw cycle at -80˚C and resuspended 
in HALT protease inhibitor cocktail (Thermo Scientific, Rockford, IL) to be analyzed for 
protein expression (SDS-PAGE), or in DETAPAC buffer for MnSOD activity.   
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Statistical Analysis 
All experiments were replicated at least in triplicate and values reported as mean 
±S.E.M. When comparing two means, Student’s t-test was used, p<0.05. When 
comparing multiple means, the results were analyzed either by one way ANOVA 
followed by Student Newman-Keuls or Kruskal-Wallis one way ANOVA on ranks tests at 
a 95% confidence interval. 
 
RESULTS 
ATRA promoted differentiated morphology, increased NF-M expression, and 
slowed proliferation of the SK-N-SH cells 
  The common mechanism by which retinoids antagonize carcinogenesis is by 
inducing differentiation and suppressing the ability of the cells to proliferate. To validate 
these therapeutic advantages of ATRA in the SK-N-SH neuroblastoma cell line, cellular 
morphology, growth rate, and expression of neurofilament-M (NF-M; an early marker of 
neuronal differentiation) were assessed. Figure 3.1A demonstrates a change in 
morphology characteristic of differentiated neurons as early as 48 hrs with ATRA 
treatment. The initiation of neurite formation (arrows) implicates the early effects of 
ATRA to promote differentiation. Images captured upon 2 weeks of continuous ATRA 
treatment (10 µM) display fully differentiated cells with very prominent neurite processes 
(arrows). These early changes in morphology are concomitant with increased 
expression of NF-M upon ATRA treatment (Figure 3.1B). Growth rates of ATRA treated 
cells were also decreased, with significant changes seen at 96 hrs (Figure 3.1C), shortly 
after increases in expression of NF-M.  
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FIGURE 3.1: ATRA PROMOTED DIFFERENTIATED MORPHOLOGY, INCREASED NF-M 
EXPRESSION, AND DECREASED NUMBER OF THE SK-N-SH CELLS.  
(A) Representative images from SK-N-SH cells treated with ATRA (10 μM) for 24hrs, 48 
hrs, and 2 wks. Arrows denote neurite formation. (B) Western Blot analysis of 
neurofilament M (NF-M) expression after treatment with ATRA (10 μM) for 24, 48, 72, 
and 96 hrs. n=5. *p < 0.05, significant difference between CON and ATRA at each time 
point. 
†
p < 0.05, significant difference between ATRA 72, 96 hrs vs. 24, 48 hrs. Kruskal-
Wallis One way ANOVA on Ranks; Student-Newman-Keuls. Results are expressed as 
fold changes vs. 24 hr CON + SEM. (C) Cell number after treatment with ATRA (10 μM) 
for 24, 48, 72, and 96 hrs. n=4. *p < 0.05, significant difference vs. 24 hr CON; 
†
p < 
0.05, significant difference between ATRA and CON at respective time point. One way 
ANOVA; Student-Newman-Keuls. Results are expressed as changes in log cell number 
+ SEM. 
 
C 
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ATRA modulates DCF (H2O2 indicator) and MitoSOX (O2
• indicator) fluorescence 
in accordance with its induction of MnSOD 
  Although other reports have investigated the generation of ROS in 
neuroblastoma cell lines (including a subclone of the SK-N-SH’s) (Erlejman and Oteiza 
2002; Nitti, Furfaro et al. 2010), the role of either O2
• or H2O2 in ATRA-induced 
differentiation of this cancer cell type is unknown. Our previous publication 
demonstrates a significant upregulation of MnSOD activity with 72 hrs ATRA treatment 
of SK-N-SH cells (Kiningham, Cardozo et al. 2008). The MnSOD enzyme scavenges 
O2
• at the mitochondrial level; yet generates another ROS, hydrogen peroxide (H2O2). 
Therefore, probing with both MitoSOX (an indicator of mitochondrial O2
•) and CM-
H2DCFDA (an indicator of intracellular H2O2) was done to assess ROS generation.  
Treatment with ATRA significantly increased MitoSOX fluorescence in comparison to 
controls at all time points (Figure 3.2A); with a major peak seen at 48 hrs, preceding the 
ATRA-mediated increase in MnSOD activity in these cells. Parallel cultures were 
incubated with rotenone (1-200 µM) as a positive control, and exhibited a concentration-
dependent increase in fluorescence (Figure 3.2B). 
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FIGURE 3.2: ATRA MODULATED DCF (H2O2) AND MITOSOX (O2
•) FLUORESCENCE IN SK-N-
SH CELLS. 
(A) MitoSOX (n=5) and DCF (n=4) fluorescence of SK-N-SH cells after treatment with 
ATRA (10 μM) for 24, 48, 72, and 96 hrs. MitoSOX: * p < 0.05 vs. CON. DCF: †p < 0.05 
vs. CON. T-test performed for each time point vs. CON. Results are expressed as fold 
changes vs. CON at each time point + SEM. (B) Rotenone treatment produced a 
concentration-dependent increase in MitoSOX fluorescence. 
A 
B 
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  As MitoSOX fluorescence returned toward baseline levels (72-96 hrs); DCF 
fluorescence significantly increased (96 hrs). Hydrogen peroxide was used as a positive 
control and also increased DCF fluorescence over that of control cells (Figure 3.3A). 
Because DCF fluoresces in the presence of other ROS besides H2O2 (i.e. peroxynitrite) 
(LeBel, Ischiropoulos et al. 1992), we used polyethylene glycol-conjugated catalase 
(PEG-Cat - 100 U/mL) to confirm that an increase in fluorescence was indicative of 
H2O2. Pretreatment of cells with PegCAT significantly attenuated the H2O2- (Figure 
3.3A) and ATRA- (Figure 3.3B) mediated increase in DCF fluorescence, suggesting that 
the nature of ATRA-generated ROS is H2O2 at 96 hrs.  
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A 
B 
FIGURE 3.3: PEGCAT-MEDIATED REDUCTION OF DCF (H2O2) FLUORESCENCE. 
DCF fluorescence of SK-N-SH cells after treatment with (A) H
2
O
2
 (0.1 μM, 20 min, 
n=4) or (B) ATRA (10 μM, 96 hr, n=3). Cells were pretreated with PegCAT (100 U/ml) 
for 3 hours prior to DCF (2.5 μM) incubation. *p < 0.05 vs. CON (-)PegCAT; 
†
p < 0.05 
vs. *. One-way ANOVA; Student-Newman-Keuls. Results are expressed as fold 
changes vs. CON (-)PegCAT + SEM. 
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ATRA’s effects on glutathione (GSH) levels; glutathione peroxidase (GPx), and 
catalase activity. 
  Given that ATRA increased DCF fluorescence (which indicates H2O2 generation) 
our next step was to determine if there was a subsequent antioxidant response by either 
glutathione (GSH), glutathione peroxidase (GPx) or catalase to degrade the H2O2. GSH 
levels were significantly decreased following ATRA treatment in comparison to non-
treated cells at all time points (Figure 3.4A). Furthermore, oxidized GSH (GSSG) was 
significantly increased in the presence of ATRA at 48hrs (3.4B).  
 GSH is a substrate used by GPx to catalyze the degradation of H2O2. Therefore, we 
postulated that ATRA may cause an increase in the activity of GPx. However, ATRA 
treatment of the SK-N-SH cells did not change GPx activity in comparison to controls at 
any time point (Figure 3.5). On the other hand, ATRA significantly increased catalase 
activity at 24 hrs, but this subsided to levels comparable to control cells by 48 - 96 hrs 
(Figure 3.6). The significant increase found in GPx and catalase activity in non-treated 
cells during the course of the experiment is consistent with previous reports 
demonstrating the ability of cells to increase activity of these enzymes as a function of 
time when cultured in vitro (Oberley, Schultz et al. 1995). Both GPx and catalase activity 
in cells treated with ATRA follow the same trend as the control cells over time. 
Altogether, elevated MnSOD, increase in DCF fluorescence, decreased GSH, and the 
lack of either GPx or catalase upregulation implicate that H2O2 becomes elevated at the 
96 hr time point and may influence neuroblastoma differentiation. 
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FIGURE 3.4: ATRA DECREASED GLUTATHIONE (GSH) LEVELS 
(A) Reduced GSH and (B) Oxidized GSH (%GSSG) levels in SK-N-SH cells after 
treatment with ATRA (10 μM) after 24-96 hrs. n=7. *p < 0.05 vs. CON per time point. T-
test performed for each time point. Results are expressed as fold change vs. CON per 
time point + SEM. 
B 
A 
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FIGURE 3.5: ATRA DID NOT SIGNIFICANTLY ALTER GLUTATHIONE PEROXIDASE (GPX) 
ACTIVITY. 
Glutathione peroxidase (GPx) activity in SK-N-SH cells after treatment with ATRA (10 
μM) after 24 (n=5), 48, 72 and 96 (n=9) hrs. T-test performed for each time point One- 
way ANOVA amongst CON and ATRA. Results are expressed as GPx activity (munits/ 
mg protein) + SEM. 
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FIGURE 3.6: ATRA’S EFFECTS ON CATALASE ACTIVITY. 
Catalase activity of SK-N-SH cells after treatment with ATRA (10 μM) for 24, 48, 72, 
and 96 hrs. n=6. *p < 0.05 vs. CON at respective time point. T-test performed for each 
time point. †p < 0.05 vs. CON 24 hrs. One way ANOVA amongst CON. Results are 
expressed as mkUnits/ mg protein + SEM. 
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Reducing MnSOD activity increased MitoSOX and decreased DCF fluorescence at 
96 hrs. 
  Several studies have investigated ROS production and antioxidant expression for 
differentiated neural cell types (Suzukawa, Miura et al. 2000; Erlejman and Oteiza 2002; 
Oh, Karlmark Raja et al. 2005; Nitti, Furfaro et al. 2010), but few provide a time-course 
analysis of these effects during the early process of differentiation. Our next step was to 
determine the effect of altering ROS by reducing MnSOD activity. By doing so, our 
studies demonstrate a change in fluorescent markers (MitoSOX and DCF) that 
coordinates with a change MnSOD activity; which scavenges O2
• and produces H2O2. 
We confirm a significant increase in activity of this isoform when treating SK-N-SH cells 
with ATRA for 72 and 96 hrs (Figure 3.7). In both control and ATRA-treated cells, 
MnSOD activity was significantly decreased in the presence of SOD2 siRNA versus 
cells receiving Ctrl siRNA for 48, 72 and 96 hrs. MitoSOX fluorescence was also 
measured to evaluate if reducing MnSOD activity influenced the generation of O2
• 
(Figure 3.8A). Again, at 24 hrs, ATRA significantly increased MitoSOX fluorescence 
versus control cells in the presence of Ctrl and SOD2 siRNA. Transfection with SOD2 
siRNA did not produce an incremental increase in fluorescence by ATRA in comparison 
to Ctrl siRNA. At 96 hrs, MitoSOX fluorescence in both Ctrl and SOD2 siRNA 
transfected cells was significantly increased by ATRA in comparison to controls. 
Furthermore, there was a significant increase in MitoSOX fluorescence when comparing 
ATRA-SOD2 siRNA to ATRA-Ctrl siRNA. (Within 96 hrs, the reduction towards baseline 
levels in control cells with ATRA treatment is apparent.) ATRA-stimulated DCF 
fluorescence was significantly attenuated when MnSOD activity was reduced with 
siRNA (SOD2 siRNA) (Figure 3.8B), implicating that MnSOD is responsible for the 
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increase in H2O2 by ATRA at 96 hrs. Induction of DCF fluorescence by ATRA was 
consistent at this time point when cells were transfected with the control siRNA 
construct. These findings support the reduction in MnSOD activity by siRNA and 
suggest that there is a corresponding increase in O2
• production at 96 hrs. 
  
FIGURE 3.7: MNSOD ACTIVITY DECREASED WITH SOD2 SIRNA. 
MnSOD activity of SK-N-SH cells after treatment with ATRA (10 μM) for 24, 48, 72, 
and 96 hrs. 24: n=3; 48-96: n=4. *p < 0.05 vs. CON at respective time point. . †p < 
0.05 vs. * Two-way ANOVA per timepoint; Student-Newman-Keuls. Results are 
expressed as fold change vs. CON + SEM per timepoint. 
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FIGURE 3.8: REDUCING MNSOD ACTIVITY INCREASED MITOSOX (O2
•) AND DECREASED 
DCF (H2O2) FLUORESCENCE AT 96 HRS. 
MitoSOX (A) and DCF (B) fluorescence in SK-N-SH cells after incubation with either a 
control vector (Ctrl-siRNA) or one targeting the MnSOD gene (SOD2-siRNA) and 
subsequent treatment with ATRA (10 μM). DCF: n=3, MitoSOX: n=8. MitoSOX: *p < 
0.01 vs. CON-Ctrl siRNA; †p < 0.05 vs. CON-SOD2 siRNA; ‡p < 0.05 vs †. T-test. 
DCF: *p < 0.001 vs. CON-Ctrl siRNA; 
†
p < 0.05 vs. CON-SOD2 siRNA; 
‡
p < 0.05 vs *. 
One way ANOVA; Student-Newman-Keuls. Results are expressed as fold changes vs. 
Mock-CON (DCF: not shown) or CON-Ctrl siRNA (MitoSOX) + SEM. 
 
  
 108  
 
Reducing MnSOD activity enhanced NF-M expression at 48 hrs but diminished it 
at 96 hrs 
  Having identified 1) an increase in MnSOD that correlates with differentiation 
(Figure 1b), and 2) appropriate changes in O2
• and H2O2 caused by reducing MnSOD 
activity (Figure 7a, b); we next determined if altering MnSOD (and therefore O2
• and 
H2O2) influenced the expression of NF-M. We demonstrate an increase in this 
differentiation marker (at 48 hrs) which is prior to the significant induction of MnSOD 
activity (at 72 hrs) by ATRA (Figure 1B). This finding is in contrast to many studies 
implicating the importance of MnSOD in differentiation (St Clair, Oberley et al. 1994; 
Cassano, Agnese et al. 2010). Secondly, reducing MnSOD activity not only enhanced 
ATRA-induced NF-M expression (ATRA-SOD2 siRNA), but it also significantly 
increased protein levels over that of the cells receiving only the control siRNA vector 
(CON-Ctrl siRNA) at 48 hrs (Figure 8a, b). This effect was lessened at 72 hrs and 
diminished at 96 hrs. Figure 8c demonstrates the significant increase in MnSOD protein 
expression in the presence of ATRA at 72 and 96 hrs, and the significant reduction of 
this antioxidant enzyme in the presence of the SOD2 siRNA at 48 and 96 hrs. Protein 
reduction is consistent with decreased MnSOD activity (Figure 3.7). Furthermore, the 
reduction in DCF fluorescence (Figure 7a) and increase in MitoSOX fluorescence 
(Figure 7b) in the presence of SOD2 siRNA substantiate a decrease in MnSOD activity. 
These data suggest that although MnSOD is not critical for initiating the differentiation 
process by neurofilament polymerization, it does promote it at the 96 hr time point. 
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FIGURE 3.9: REDUCING MNSOD ACTIVITY ENHANCED NF-M EXPRESSION AT 48 HRS BUT 
DIMINISHED IT AT 96 HRS. 
Western Blot analysis of (A,B) NF-M and MnSOD (A,C) in SK-N-SH cells after 
incubation with either a control vector (Ctrl siRNA) or one targeting the MnSOD gene 
(SOD2 siRNA) and subsequent treatment with ATRA (10 μM) for 48, 72, and 96 hrs. 
n=6. *p < 0.05 vs. CON-Ctrl siRNA per time point, †p < 0.05 vs *. Kruskal-Wallis one 
way ANOVA on ranks. Results are expressed as fold changes vs. CON-Ctrl siRNA per 
time point + SEM. 
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PegCAT treatment influenced NF-M expression in a similar manner to reducing 
MnSOD activity 
  To provide evidence for a role of H2O2 in ATRA-mediated induction of NF-M 
expression, we incubated the cells continuously in the presence of PegCAT for 24-96 
hrs. Western blot analysis demonstrated that PegCAT treatment influenced the 
expression of NF-M in a similar manner to the SOD2 siRNA construct (Figure 9a, b). 
Although there was no significant enhancement of NF-M expression at 48 hrs by 
PegCAT treatment, it is apparent that any up-regulation of NF-M expression by ATRA 
was lost by 96 hrs. These findings parallel those found by reducing MnSOD activity. 
DCF-analysis revealed no significant decrease in H2O2 content after 96 hrs of 
continuous PegCAT treatment (data not shown). However, there is an immediate 
reduction of intracellular H2O2 within 3 hrs of treatment (Figure 3). These data altogether 
support a role for H2O2 to potentiate expression of this differentiation marker at 96 hrs. 
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FIGURE 3.10: PEGCAT TREATMENT INFLUENCED NF-M EXPRESSION IN A SIMILAR MANNER 
TO REDUCING MNSOD ACTIVITY.  
(A,B) Western Blot analysis of neurofilament M (NF-M) expression in SK-N-SH cells 
after 24 hr pre-incubation with PegCAT (100U/mL) and subsequent treatment with 
ATRA (10 μM) for 48, 72, and 96 hrs. n=6. *p < 0.05, significant difference vs. CON 
(-)PegCAT; Kruskal-Wallis one way ANOVA on ranks. †p < 0.05, significant 
difference vs. CON (-)PegCAT; One way ANOVA; Student-Newman-Keuls. Results 
are expressed as fold changes vs. CON (-)PegCAT per time point + SEM. 
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DISCUSSION 
  An in vitro model of neuroblastoma, the SK-N-SH cells are composed of three 
distinct cell types (epithelial, neuronal, and intermediate) and are sensitive to retinoid-
induced growth inhibition and formation of neurite extensions. Sidell et al. demonstrate 
that growth inhibition and differentiation are commonly associated with a decreased 
malignant phenotype (Sidell, Altman et al. 1983). We confirm these observations by 
identifying NF-M as an early neuronal differentiation marker whose protein expression 
increases two days prior to growth suppression by ATRA. In parallel to these changes, 
ATRA causes the upregulation of the essential antioxidant mitochondrial enzyme, 
MnSOD. The importance of the mitochondria in differentiation is well supported in other 
neuronal models. In HN9.10e hippocampal neuroblasts, retinoic acid-induced neurite 
formation also stimulated remodeling and fusion of the mitochondria, collective 
distribution throughout the neurites, and an increase in mitochondrial potential (Voccoli 
and Colombaioni 2009). These effects were observed very early (within 1 hr) using 
retinoic acid concentrations 10-fold less than those used in the current study. Schneider 
et al. validated this finding by showing an increase in mitochondrial membrane potential 
during ATRA-induced differentiation of SH-SY-5Y cells (a subclone of the SK-N-SH 
population) (Schneider, Giordano et al. 2011). The authors also demonstrated 
distribution of the mitochondrial network throughout the neurites and, in accordance with 
our findings, an increase in MnSOD expression.  
  There is a strong correlation between an increase in mitochondrial membrane 
potential and the production of ROS (Korshunov, Skulachev et al. 1997; Turrens 2003). 
Using an indicator of mitochondrial O2
• (MitoSOX), we observed an increase in MitoSOX 
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fluorescence in the presence of ATRA. Important for the current study, retinoids, 
including ATRA, generate ROS in both acute promyelocytic leukemia patients and the 
human promyelocytic leukemia cell line (HL-60). Moreover, leukocytes characteristically 
produce ROS, in particular O2
•, which is correlated with their differentiation (Yen and 
Albright 1984; Chomienne, Ballerini et al. 1990). We observed that the increase in 
MitoSOX fluorescence in the SK-N-SH cells is sustained for at least 96 hrs. However, a 
closer examination at the flux in fluorescence over time suggests that O2
• levels return 
to baseline levels at the same time point (72 hrs) that we have established a significant 
increase in ATRA-mediated MnSOD activity (Kiningham, Cardozo et al. 2008). The 
increase in DCF fluorescence (and subsequent attenuation by PegCAT treatment) at 96 
hrs further suggests that production of H2O2 parallels an increase in MnSOD activity. 
These studies significantly contribute to the field by providing a time-course analysis of 
both O2
• and H2O2 generation that coordinates with MnSOD activity. Furthermore, 
specifically identifying that abrogation of H2O2 limits the expression of NF-M provides a 
greater understanding of H2O2 as an important signaling molecule in this classic model 
of neuronal differentiation.   
  In order to get a more complete view of the redox status of the SK-N-SH cells in 
the presence of ATRA, we also assessed GSH content, GPx and catalase activity. Each 
of these endogenous antioxidant defense systems is integral in the handling of H2O2. 
Glutathione exhibits antioxidant properties by reducing H2O2, various hydroperoxides 
(ROOH), and lipid peroxides and plays a major role in maintaining cellular redox 
homeostasis (Dickinson and Forman 2002). Many studies also implicate GSH as an 
essential mediator of cellular proliferation (Reddy, Kleeberger et al. 2007; Reddy, 
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Kleeberger et al. 2007). In this study, we made the novel finding that ATRA significantly 
reduces GSH levels in neuroblastoma cells. Although cAMP treatment of the IMR-32 
neuroblastoma cell line resulted in a reduction of GSH, which was enhanced by ATRA, 
there was no significant change in GSH levels in the presence of ATRA alone 
(Carystinos, Alaoui-Jamali et al. 2001). This could be explained by MYCN amplification, 
which is reportedly responsible for increased GSH biosynthesis (in comparison to 
neuroblastoma subtypes without MYCN amplification) and resistance to oxidative stress 
(Veas-Perez de Tudela, Delgado-Esteban et al. 2010). Therefore, in the case of IMR-32 
cells, ATRA treatment may have been insufficient to overcome higher basal levels of 
GSH. 
  The GPx enzyme was also assessed due to the fact that it uses GSH as a 
substrate for scavenging peroxides. However, we discovered no significant change in 
GPx activity in the presence of ATRA at any time point (24-96 hrs). These data 
implicate that ATRA functions by a different mechanism by which to decrease GSH. 
Several groups have examined the role of nuclear factor erythroid-derived 2 (Nrf2), 
which is also ROS-responsive and a master regulator of GSH-biosynthesizing enzymes. 
Using the same concentrations as our study (10 μM), Zhao et al. show that retinoic acid 
upregulates the Nrf2 antioxidant response system within 24 hrs in the SH-SY-5Y cells 
(Zhao, Wu et al. 2009). Although the authors demonstrated increased expression of the 
Nrf2 target, NAD(P)H quinone reductase (NQO1), it was not established whether GSH 
levels were elevated. These cells are a subclone of the SK-N-SH cells and may respond 
differently in respect to the lack of neighboring non-neuronal cells (i.e. S-type: 
epithelial). Otherwise, in contrast to our study, Zhao et al. did not include sodium 
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pyruvate in their culture medium. This potent antioxidant attenuates H2O2 generation 
(O'Donnell-Tormey, Nathan et al. 1987; Wang, Perez et al. 2007), and its absence 
might allow for ROS-upregulation of the classic Nrf2-antioxidant response. In contrast, 
Wang et al. demonstrated a direct retinoic acid receptor (RAR)mediated effect by 
showing that ATRA caused suppression of Nrf2 activity by liganded RAR, inhibiting 
recruitment of Nrf2 to the ARE (antioxidant response element) in MCF-7 breast cancer 
cells (Wang, Hayes et al. 2007). Despite being performed in a different cell type, the 
latter studies used 10-fold less retinoic acid (1 μM) which may not elicit the same 
oxidative response. Therefore, future work is needed to establish if Nrf2 is playing a role 
in the reduction of GSH by ATRA in the SK-N-SH cells.    
  Catalase, another endogenous antioxidant, is found predominantly in 
peroxisomes and catalyzes the conversion of H2O2 to water and molecular oxygen (O2) 
(Valko, Rhodes et al. 2006). In the current study, we demonstrated a 1.5 fold increase in 
catalase activity by ATRA within 24 hrs. Differentiation of Neuro2A mouse 
neuroblastoma cells with ATRA increased catalase activity by a similar magnitude. 
However, in contrast to our findings, activity increased more (~2.5 fold) after 48 hrs of 
ATRA treatment (Shinjyo and Kita 2007). Disparities may be explained based on their 
use of a much higher concentration of ATRA (20 μM), or our inclusion of sodium 
pyruvate (1 mM) in the growth media. Additionally, in contrast to their study using a 
different fluorescent probe (commercial name: BES-H2O2), we do not report a significant 
increase in H2O2 production by evaluating DCF fluorescence. However, the slight 
increase observed in the current study may be physiologically relevant to stimulate 
catalase activity. Detection of H2O2 could be 1) abrogated by the use of sodium 
  
 117  
 
pyruvate or 2) made attainable by a more sensitive method. Nonetheless, a lack of 
increased catalase activity at 96 hrs in the current study suggests that catalase does not 
act as an antioxidant defense in the event of H2O2 generation at 96 hrs. Decreased 
catalase activity is associated with increased differentiation of IMR-32 neuroblastoma 
cells (Erlejman and Oteiza 2002). Furthermore, addition of catalase decreased neuronal 
differentiation of PC12 cells (Suzukawa, Miura et al. 2000). Accordingly, there is 
growing evidence for the role of H2O2 to be a key signaling molecule and regulate gene 
expression in many cellular models (as reviewed in (Allen and Tresini 2000)). 
Particularly, in differentiated SH-SY-5Y cells subacute amounts of H2O2 significantly 
upregulated levels of the dopamine D2 receptor (key to regulate neurotransmission) and 
increased NF-κB activation (Larouche, Berube et al. 2008). Our previous reports 
support a role for NF-κB in differentiation of SK-N-SH cells; future work needs to 
address if H2O2 generation contributes to the activation of this transcription factor.   
  We have demonstrated that ATRA up-regulates the expression of NMDAR1 
(Kiningham, Cardozo et al. 2008) and NF-M (at 48 hrs) prior to a significant increase in 
MnSOD activity (at 72 hrs). This suggests that MnSOD is not essential to initiate 
differentiation. However, an interesting finding is that a reduction of MnSOD activity 
enhanced NF-M expression. Rather than directly affecting target proteins, slight 
changes in MnSOD may alter the redox status (i.e. through O2
• and H2O2) to influence, 
for example, the polymerization of NF-M. The stability and structure of intermediate 
filament proteins such as NF-M have been shown to be susceptible to damage by 
oxidative stress (Gelinas, Chapados et al. 2000). The relative ratios of these ROS may 
therefore affect NF-M stability and function. The attenuation of increased NF-M 
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expression by ATRA during MnSOD inhibition seen at 96 hrs should be noted when 
considering a role for MnSOD (and possibly H2O2) in differentiation at a later time point. 
Additionally, the current study investigates relative changes in ROS (O2
• and H2O2) 
during the differentiation process, whereas many studies examine one time point and 
may overlook the unique roles each of these play. The generation of H2O2 by MnSOD 
might function to further the differentiation process at 96 hrs and beyond. Otherwise, 
considering that MnSOD is well known to promote cell survival, differentiation cells (at 
48 hrs) may subsequently undergo apoptosis (at 96 hrs). Long-term retinoid treatment 
of the SK-N-SH cell line, comprised of both epithelial (S-type) and neuronal (N-type) 
cells, induces death of the S-type and differentiation of the N-type (Melino 1994). 
Therefore, in this model, future work should investigate if the N-type cell population is 
subject to apoptosis by reducing MnSOD activity. These findings would hold potential to 
improve retinoid therapy by augmenting the differentiation process earlier and 
subjecting differentiated cells to apoptosis.   
  Supporting the results obtained via silencing MnSOD, we also demonstrate a 
similar trend in ATRA-induced NF-M expression by pretreatment of the SK-N-SH cells 
with the PegCAT construct. Determination of DCF fluorescence (i.e. H2O2) in the 
presence of PegCAT for 96 hrs revealed neither a significant decrease in comparison to 
controls, nor the attenuation of an ATRA-mediated increase (data not shown). Therefore 
the reduction of fluorescence by PegCAT immediately (within 3 hrs of treatment) (Figure 
3a,b) may have been sufficient to alter the expression of the NF-M protein particularly at 
the 96 hr time point. These data, along with that obtained by reducing MnSOD activity, 
suggest that the rise in H2O2 levels at 96 hrs is important to maintain NF-M protein 
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levels, and subsequent reduction can reduce expression of such a differentiation 
marker.  
CONCLUSIONS 
 Reactive oxygen species have received a lot of attention in the past few decades 
because they are generated by all aerobic organisms and are known to be involved in a 
variety of cellular responses, both harmful and beneficial. Moreover, the various 
antioxidant defense systems within cells have been intensely studied in light of their 
capacities to influence gene expression in many in vitro and in vivo models. Although 
the generation of ROS is often associated with damaging effects, they also play an 
essential role in key signal transduction pathways that are involved in the processes of 
cellular proliferation, apoptosis, cell cycle arrest, and differentiation (as reviewed in 
(Valko, Rhodes et al. 2006)). Here we closely examine the redox status of the SK-N-SH 
cells as determined by the generation of ROS and antioxidant expression. We have 
identified H2O2 as a potential signaling molecule to promote neuronal differentiation. Our 
previous work demonstrated NF-κB regulation of both MnSOD and differentiation; 
therefore, current findings compel us to investigate if this is mediated by H2O2 
generation. We hypothesize that reducing MnSOD activity early on in retinoid 
treatments may stimulate early differentiation of neuroblastoma cells. If MnSOD-
mediated H2O2 generation is important to promote differentiation at a later time point in 
therapy, early interventions preventing H2O2 degradation could nevertheless provide 
potential benefits. Incorporation of other immortalized neuroblastoma cell lines in these 
studies will be important as a next step to assess the responsiveness of a wide range of 
subtypes to such alteration of redox status. Meanwhile, the clinical impacts of these 
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findings suggest that retinoid treatment can be tailored to closely regulate ROS and 
antioxidant expression for optimized differentiation therapy. 
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CHAPTER 4: ASSESSMENT OF CELL CYCLE DISTRIBUTION AND 
APOPTOSIS UPON REDUCING MNSOD ACTIVITY 
INTRODUCTION 
Attenuation of proliferation is also an important factor in the process of 
differentiation. Cancer is defined by a lack of controlled proliferation; therefore, any 
therapy capable of slowing or stopping this process should provide benefit by ultimately 
reducing tumor cell number. The MnSOD antioxidant enzyme is essential for the 
survival of all oxygen metabolized cells (McCord, Keele et al. 1971). Furthermore, Zhao 
et al. demonstrated that MnSOD overexpression in mouse fibrosarcoma cells 
attenuated apoptosis as it promoted a more differentiated phenotype (Zhao, Kiningham 
et al. 2001). Therefore, the current chapter focuses on ATRA-mediated changes in cell 
cycle distribution and apoptotic markers in the presence of SOD2 siRNA to investigate 
the reduction of NF-M within 96 hrs of ATRA-SOD2 siRNA treatment. 
METHODS 
Cell cycle analysis 
Cells were plated at a density of 3 x 104 cells/ cm2. At the completion of 
treatments, cells were harvested via trypsinization, centrifuged at 2 000 rpm for 5 min at 
4°C, washed once in PBS working solution (PBS-WS: PBS + 1% FBS), centrifuged 
again, and resuspended in 100 μL PBS-WS. 900 μL 70% ethanol was added to the 
cells while simultaneously vortexing at low speed. Cells were fixed for at least 24 hrs at 
4°C. After fixing, cells were washed twice in PBS-WS, centrifuged, resuspended in 300 
μL (PI) staining solution (in PBS: 10 μg/mL PI; 0.25 mg/mL RNase A) and incubated for 
30 min at room temperature. Fluorescence was analyzed on the Accuri C6 Flow 
Cytometer using CFlow Plus Analysis software. 
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Caspase 3 protease activity 
Caspase-3 activity was assessed using proteolytic cleavage of the fluorophore 7-
amino-4-trifluoromethyl coumarin (AFC) from the substrate conjugate, DEVD-AFC 
(ApoAlert assay kit; Clontech Laboratories, Palo Alto, CA). An equal volume (50 μl) of 
each sample was incubated with DEVD-AFC in the presence of 10 mM dithiothreitol, for 
1 hr at 37oC. AFC was detected using a 400-nm excitation filter and a 505 nm emission 
filter by means of the Gemini XPS fluorescent microplate reader (Molecular Devices, 
Sunnyvale CA) equipped with SoftMax Pro software. The data obtained was normalized 
to protein content measured with the BioRad protein assay using bovine serum albumin 
as the standard. The results are reported as fold change in caspase-3 activity vs. CON. 
AnnexinV/ 7AAD apoptosis assay 
Cells were plated 24 hrs before initiation of treatments at a density of 3 x 104 
cells/ cm2. Cells were collected by trypsinization, rinsed twice with PBS, and 
resuspended in either 1) neither reagent (negative control), 7-AAD alone (1 μg/mL), or 
7-AAD + Annexin V (1 mg/mL) in binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM 
NaCl, 2.5 mM CaCl2). Fluorescence was then measured (excitation at 494 nm, emission 
at 518 nm). 
RESULTS AND DISCUSSION 
Treatment of the SK-N-SH cells with ATRA significantly decreases cell number 
by ~96 hrs. Therefore, we analyzed cell cycle distribution at earlier time points to track 
initial ATRA-induced changes alone and when combined with an inhibition of MnSOD 
activity (Figure 4.1). As early as 48 hrs, ATRA significantly increased %G1 phase 
distribution in the SK-N-SH cells, which is consistent with published literature (Giannini, 
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Dawson et al. 1997). We expected a more pronounced increase of %G1 phase 
distribution in the presence of SOD2 siRNA (due to the enhancement of NF-M 
expression under these conditions). However, this relationship was not observed. The 
decrease in ATRA-mediated NF-M expression at 96 hrs by reducing MnSOD activity 
might be expected to decrease %G1 and increase %S phase distribution in comparison 
to ATRA alone. The cell population may no longer be differentiating, yet may re-enter 
the cell cycle, which would translate into an increase of cells in S phase. In this 
scenario, we must consider three possibilities: differentiation, proliferation, and 
apoptosis. If MnSOD is important to promote differentiation at 96 hrs, does reducing its 
activity allow re-entry into the cell cycle and proliferation? Or are the cells more 
vulnerable to apoptosis? Cell cycle analysis demonstrated that ATRA treated cells 
receiving SOD2 siRNA did not decrease %G1 phase distribution in comparison to 
ATRA-Ctrl siRNA cells, thus suggesting that proliferation rates were not changed. 
MnSOD is a well-established tumor suppressor and inhibits cell growth in several cell 
types (Li, Oberley et al. 1998; Li, Yan et al. 2000; Oberley 2005). However, a reduction 
of MnSOD and the increase in O2
• at 96 hrs might result in cell death. This is supported 
by evidence from Lu et al. showing NADPH oxidase-mediated O2
• generation and 
neonatal neuronal cell death (Lu, Wainwright et al. 2012).   
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FIGURE 4.1: CELL CYCLE ANALYSIS IN THE PRESENCE OF SOD2 SIRNA.  
Cell cycle analysis of SK-N-SH cells after treatment with ATRA (10 μM) for 48, and 96 
hrs. n = 3. *p < 0.05 vs. CON-Ctrl siRNA. One way ANOVA; Student-Newman-Keuls. Data 
are represented as % distribution of cells per cell cycle phase + SEM. 
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As discussed in Chapter 1, MnSOD is necessary for survival of all oxygen-
metabolizing cells (McCord, Keele et al. 1971). We considered that reduction of ATRA-
mediated NF-M expression at 96 hrs in SOD2 siRNA transfected cells was due to 
increased cell death. Therefore, the activity of caspase 3 (a common regulator of the 
apoptotic cascade), and AnnexinV/ 7AAD staining (also present in apoptotic cells) was 
measured in the presence of SOD2 siRNA. In the presence of Ctrl siRNA, at all time 
points, ATRA decreased the activity of caspase 3 (Figure 4.2). This finding is in 
accordance with previous work in our lab which showed that ATRA attenuates cellular 
FIGURE 4.2: CASPASE-3 ACTIVITY IN THE PRESENCE OF SOD2 SIRNA.  
Caspase-3 activity of SK-N-SH cells after treatment with ATRA (10 μM) for 48, 72, and 
96 hrs. n = 3. *p, †p, ‡p < 0.05. One way ANOVA; Student-Newman-Keuls. Data points 
were normalized to CtrlsiRNA-CON at 48 hrs + SEM.  
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death mediated by cisplatin (CDDP). It remains unclear as to why overall caspase 3 
activity is decreased in the presence of SOD2 siRNA versus Ctrl siRNA transfected 
cells. However, Ctrl siRNA transfected cells seemed to exhibit more cell death than 
SOD2 siRNA transfected cells (qualitative observation). “Mock transfected cells” 
(Hiperfect only) were not analyzed; this may have revealed increased caspase 3 activity 
with SOD2 siRNA. Nonetheless, upon reducing MnSOD activity, ATRA significantly 
decreased caspase 3 activation as compared to controls at 48 hrs, but not at 72 or 96 
hrs. In other words, cells lacking MnSOD for an extended time period may be more 
vulnerable to apoptosis in the presence of ATRA.  
Apoptosis was also monitored in cells using a double-labeling assay with 
Annexin V and 7-Amino-actinomycin D (7-AAD) (Figure 4.3A, B). Annexin V binds to 
phosphatidylserines that are flipped from the cytoplasmic side of cellular membranes to 
the extracellular side in apoptotic cells. 7-AAD intercalates into double-stranded nucleic 
acids via penetration into cellular membranes of dying cells. Early apoptotic cells are 
represented in the lower right quadrant, and late apoptotic cells in the upper right. 
Figure 4.3B is a graph representing the flow cytometry data in 4.3A. ATRA reduced 
early apoptosis as compared to controls better in MOCK transfected cells (hiperfect 
only) than in those receiving Ctrl siRNA. In accordance with observations and caspase 
3 activity, Ctrl siRNA appears to impart non-specific toxicity. However, ATRA did not 
reduce early apoptosis in SOD2 siRNA transfected cells in comparison to Ctrl siRNA 
cells. The percentage of cells found in their late apoptotic stage follows a similar trend 
with the respective treatments. However, SOD2 siRNA transfected cells had a much 
more pronounced percentage of cells in this stage versus Ctrl siRNA transfected cells. 
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These experiments are preliminary (n=1) and required replication, however, it is 
apparent that these data correlate closely with the caspase 3 activity data. 
Our data indicate that changes in cell cycle distribution caused by ATRA are not 
significantly augmented by reducing MnSOD expression. However, caspase 3 analysis 
implicated increased apoptotic events at 72 and 96 hrs in ATRA-SOD2 siRNA treated 
cells versus those receiving ATRA alone (ATRA-Ctrl siRNA). These results suggest that 
MnSOD is a survival factor and when reduced can render this cell type subject to 
apoptosis. Annexin V staining concurs with this theory in terms of late apoptotic cells. 
Considering also that reducing MnSOD at 48hrs enhanced NF-M expression, we 
hypothesize that under these conditions, differentiating neurons whose MnSOD 
expression is reduced, are undergoing apoptosis at 96 hrs. If clinicians can tailor 
neuroblastoma therapy to promote death of differentiated cells, this might avoid the 
undesirable effects of chemo- or retinoid resistance in patients. 
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FIGURE 4.3: ANNEXIN V/7AAD ANALYSIS IN THE PRESENCE OF SOD2 SIRNA.  
AnnexinV/7AAD staining of SK-N-SH cells after incubation with either a control vector 
(Ctrl-siRNA) or a vector targeting the MnSOD gene (SOD2-siRNA), and subsequent 
treatment with ATRA (10 μM) for 96 hrs. n = 1. *, †, ‡p < 0.05 vs. CON at respective time 
point. (A) Flow cytometry and (B) graphical representation. Lower right quadrant: early 
apoptotic. Upper right quadrant: late apoptotic. Results are expressed as % occurrence 
in designated apoptotic stage. 
B 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 The body of work performed and compiled in the previous chapters proposes that 
the redox status influences the process of differentiation stimulated by ATRA in 
neuroblastoma cells. Figure 5.1 outlines a time-course analysis of ATRA’s effects on the 
specified ROS and markers of differentiation.  
 
 
 
 
FIGURE 5.1: TIME-COURSE ANALYSIS OF ATRA’S EFFECTS ON ROS AND DIFFERENTIATION OF 
SK-N-SH CELLS. 
Time-course analysis of SK-N-SH cells after treatment with ATRA (10 μM) for 24-96 
hrs. NC: no change; na: data not available; (+) increases or (-) decreases versus 
controls; * Reveals significance: p < 0.05. 
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Our first study demonstrated ROS (i.e. O2
•) generation and decreased GSH 
levels in the SK-N-SH neuroblastoma in vitro model upon differentiation by ATRA. 
Differentiation of the SH-SY-5Y neuroblastoma line is reportedly facilitated by increased 
O2
• (Nitti, Furfaro et al. 2010); however it is still unknown if and what role O2
• plays in the 
SK-N-SH cells. Additional studies must address the mechanism of ATRA-induced O2
•. 
Nonetheless, because we observed decreased GSH levels, we supplemented ATRA 
treatments with N-acetyl-L-cysteine (NAC), which is used commonly to stimulate GSH 
biosynthesis. The original hypothesis was that the differentiation process would be 
attenuated. Conversely, NAC augmented ATRA-mediated differentiation and reduction 
of cell number in this model. Therefore, we proposed a novel, therapeutic application for 
NAC, which is already FDA approved and safe for administration to patients (i.e. for 
acetaminophen toxicity).  
ATRA therapy is often met with chemoresistance. We suggest ROS induction 
may limit its effectiveness and that supplementation with NAC can have significant 
clinical implications to improve a treatment regimen with retinoids. ATRA itself is redox 
sensitive (Adamson 1996). Further oxidation may be prevented either by NAC, or its 
subsequent generation of GSH. Either of these may explain a method by which NAC 
increases ATRA’s bioavailability to promote differentiation. Further inspection proposes 
that NAC’s effects may be manifested at the level of the RAR. The addition of NAC in 
culture might sustain a more reduced environment within the nucleus, thereby 
promoting RAR-RXR binding to the RARE, increasing expression of proteins essential 
for neuronal differentiation (i.e. NF-M, NMDAR1). We have supporting data from our 
previous publication for NMDAR1 expression to be downstream from NF-κB activation. 
A more reduced nuclear environment would also be permissive for NF-κB binding to 
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DNA. In consideration of these possibilities, it is uncertain if NAC could traverse the 
nuclear membrane. It would be more likely that GSH (generated via NAC pretreatment) 
is transported into the nucleus to influence the nuclear redox state. Circu et al. 
demonstrate in colonic epithelial cells that inhibition of GSH transport to the 
mitochondria blocks NAC-mediated protection from apoptosis (Circu, Rodriguez et al. 
2008). Their results suggest mitochondrial GSH content to be more crucial than 
cytosolic localization for defending against ROS-induced cell death.  
As discussed above, a novel discovery in the first study was that ATRA 
significantly decreased GSH levels in a neuroblastoma cell line. The concomitant 
generation of O2
• within the same time frame might beg the question of whether or not 
the lowered GSH permits an increase in O2
•. However, this possibility is unlikely due to 
the fact that GSH is more important for hydroperoxide removal (Dickinson and Forman 
2002). There are many studies implicating that either decreased GSH levels or an 
oxidative environment enhances cellular differentiation and/ or decreases proliferation 
(Atzori, Dypbukt et al. 1994; Aw 2003; Reddy, Kleeberger et al. 2007; Reddy, 
Kleeberger et al. 2007). Furthermore, Pallardo et al. provide an excellent review 
highlighting the importance of GSH nuclear localization during proliferation (Pallardo, 
Markovic et al. 2009). Our studies focused on whole cell GSH localization. Future 
studies will aim to measure all possible compartments for this GSH; including cytosolic, 
mitochondrial, and nuclear. Of equal importance in this model might be ATRA-regulation 
of Nrf2, an essential transcription factor involved in the biosynthesis of GSH. Increased 
GPx activity can reduce GSH; however, the lack of GPx upregulation by ATRA (Chapter 
3) concomitant with a decrease in GSH provides additional reason to investigate Nrf2 
activity. Future work would be necessary to determine if either knocking down Nrf2 or 
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expression or supplementing the system with BSO (inhibitor of GSH synthesis) mimics 
the effects of ATRA on differentiation. However, preliminary data (data not shown) 
suggests that BSO supplementation does not influence ATRA-induced NF-M 
expression. This concept sounds counterintuitive given the ability of NAC (inducer of 
GSH synthesis) to enhance expression of both NMDAR1 and NF-M. Nonetheless, when 
administering exogenous supplements or making genetic modifications, it is essential to 
consider the relative ROS levels and antioxidant activity; because these can govern 
activation/ deactivation of downstream targets (Li, Oberley et al. 1998). Again, oxidative 
stress is dependent on the balance of ROS and antioxidants and each cell type also 
possesses a different antioxidant capacity. For example, MYCN-amplified 
neuroblastoma cells (IMR-32, SJ8, SJNB10) reportedly have higher basal GSH levels 
and resistance to oxidative stress in comparison to their non-MYCN-amplified 
counterparts (Veas-Perez de Tudela, Delgado-Esteban et al. 2010). Even the same 
cancer cell types can respond differently to parallel treatments. Therefore, measuring 
cellular/ nuclear redox status is an important experimental step in research that involves 
ROS signaling. 
Together, these findings raise an interesting question: does the induction of ROS 
by/ or the auto-oxidation of ATRA decreases its effectiveness in neuroblastoma patients 
by provoking resistance to either retinoids themselves or chemotherapeutic drugs (i.e. 
cisplatin and paclitaxel) (Lasorella, Iavarone et al. 1995; Freemantle, Spinella et al. 
2003)? Although we discovered that ATRA pretreatment of SK-N-SH cells confers 
protection against cisplatin (CDDP)-induced cell death (unpublished data), it is uncertain 
if there is a role played by ROS under these conditions. In order to address these 
proposed mechanisms, it would be necessary to 1) explore the redox state of the 
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nucleus, 2) identify RNA transcripts of NF-M and NMDAR1, and 3) determine each of 
the aforementioned instances in the presence of a reagent(s) that will knowingly 
produce a more oxidized or reduced nuclear environment.  
Our second study investigates the essential nature that MnSOD plays in the 
differentiation of neuroblastoma. Based on this work, that published by Kiningham et al. 
(Kiningham, Cardozo et al. 2008), and unpublished data from our laboratory, there is an 
intricate web of signaling mechanisms that have the potential to influence the 
differentiation status of the SK-N-SH cells. Despite demonstrating the simultaneous 
effects of NAC to enhance ATRA-induced differentiation and expression of the RAR 
target protein (CRABP-II) in the above studies, the exact role of RAR remains to be 
determined. The RAR-RXR receptor and NF-κB binding to DNA each likely contributes 
to the differentiation of this cell type by ATRA. Furthermore, although we have found 
that knocking down RAR results in an attenuation of ATRA-induced MnSOD protein 
expression, future work must identify the subsequent degree of differentiation under 
these conditions. 
 In the SK-N-SH cells, ATRA not only promotes DNA binding, but it also increases 
SOD2-luciferase promoter activity via NF-κB (data not shown). Thus, it is apparent that 
MnSOD is responsive to NF-κB in this model. Moreover, our recent publication 
demonstrates that inhibiting nuclear translocation of the NF-κB p50 subunit resulted in 
decreased MnSOD and NMDAR1 expression (Kiningham, Cardozo et al. 2008). These 
studies would suggest that MnSOD is important for the expression of NMDAR1. 
However, as also demonstrated in the current studies, induction of both NMDAR1 and 
NF-M occurs prior to ATRA-stimulated MnSOD activity. Both of these findings signify 
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that this antioxidant is not essential to initiate neural differentiation, yet provide evidence 
for the importance of basal MnSOD activity during this process. Differentiation is not a 
single event; many proteins are important to promote neuron maturation at different 
stages than for NMDAR1 or NF-M expression (i.e. MAP2, Tau, NeuN). Despite the 
above results, we investigated the effects of reducing MnSOD activity on SK-N-SH 
differentiation. In accordance with many studies implicating the importance of MnSOD 
to promote differentiation, ATRA-mediated induction of NF-M at 96hrs was abrogated by 
reducing MnSOD. However, contrary to our expectations, NF-M expression was 
enhanced at 48 hrs under the same conditions. In our first study (Chapter 2), we 
suggested that the significant increase in O2
• within 24-48 hrs of ATRA could limit its 
effectiveness to induce differentiation via promoting an oxidative environment. 
Questions that surfaced from that study were: are O2
• levels further increased between 
24-48 hrs when reducing MnSOD and do they play a role to promote differentiation? 
Analysis of MitoSOX fluorescence established that there is no enhancement of ATRA-
generated O2
• in the presence of SOD2 siRNA at 24 hrs. Likewise, there is no 
significant decrease in MnSOD activity with SOD2 siRNA in comparison to Ctrl siRNA 
transfected cells. The O2
• generation by ATRA is likely causative for MnSOD 
upregulation, as demonstrated in Figure 3.2. However, it is not accurate to assume that 
this event is important for differentiation; or at this stage of differentiation when NF-M 
expression increases. To delineate a potential role of ATRA-induced O2
• within the first 
24-48 hrs, future experiments can aim to overexpress MnSOD and subsequently 
assess markers of differentiation and proliferation status.  
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Chapter 3 also examines the production H2O2 and specific antioxidants (GSH, 
GPx, catalase) that are responsible for its degradation. We show in the SK-N-SH cells 
that ATRA generates H2O2 more significantly than controls within 96hrs; which is likely 
the result of increased MnSOD activity. Despite the lack of increased DCF fluorescence 
with ATRA between 24-72 hrs, basal MnSOD activity may generate low levels 
(undetectable by DCF) of H2O2 that inhibit polymerization of the redox sensitive NF-M 
protein. By reducing MnSOD activity, subsequently reduced H2O2 levels could allow for 
efficient NF-M polymerization. The similar results on NF-M expression obtained with 
PegCAT treatments support this idea. Overexpression of catalase will provide additional 
information on the importance of H2O2 during the differentiation process. Furthermore, 
because we have previously demonstrated NF-κB regulation of both MnSOD and 
differentiation (NMDAR1 expression) (Kiningham, Cardozo et al. 2008), future work will 
investigate if the nature of NF-κB activation is via H2O2 generation. 
Another possible mechanism for enhanced NF-M expression by reducing 
MnSOD activity could be explained by studies performed by Crow et al. Interestingly, 
the authors demonstrate SOD1 (CuZnSOD)-catalyzed nitration of neurofilament L (NF-
L) proteins in the presence of ONOO- (Crow, Sampson et al. 1997; Crow, Ye et al. 
1997). The authors propose that in the presence of a high NO concentration, its reaction 
with SOD is three times faster than the dismutation of O2
•. As discussed above, NO and 
O2
• combine to form ONOO-, which can subsequently form a nitronium-like nitrating 
molecule with SOD. The close proximity of NF-L, which has a high affinity for the zinc 
cation (in CuZnSOD), then results in nitration of tyrosine residues, structurally interfering 
with polymerization or associations with other NF subunits (NF-M, NF-H). No such 
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relationship has been demonstrated for the MnSOD isoform and NF-M; however, these 
findings are worth noting. In order to investigate this possibility, future experiments must 
address the presence of NO and ONOO- in our system with ATRA treatment. 
The clinical impact of these findings might demonstrate that reducing MnSOD 
activity initially during retinoid treatments may stimulate early differentiation of 
neuroblastoma cells. Otherwise, if MnSOD-mediated H2O2 generation is important to 
promote differentiation at a later time point in therapy, preventing degradation of or 
scavenging H2O2 could provide potential benefits. It is well established that 1) a loss of 
MnSOD promotes cell death and 2) differentiated cells are often resistant to apoptosis 
(Lombet, Zujovic et al. 2001). Therefore, further investigation into the levels of apoptosis 
achieved with reducing MnSOD activity needs to be performed. Moreover, we propose 
that the fate of the differentiated cells, i.e. those positive for the N-type, and NF-M/ 
NMDAR-1 expression, be examined for their apoptotic fate. 
In conclusion, our work suggests that both ROS and MnSOD contribute to the 
effectiveness of ATRA-mediated differentiation of neuroblastoma cells (Figure 5.2). 
Utilizing the antioxidant, NAC, we demonstrate increased effectiveness of ATRA to 
induce expression of differentiation markers (NF-M, NMDAR1) and reduce cell number. 
Secondly, although expression of these markers occurs prior to ATRA-induced MnSOD 
activity, it is apparent that baseline MnSOD levels play an important role to modulate at 
least one of these proteins (NF-M). Furthermore, assessment of key endogenous 
antioxidants (GSH, GPx, catalase) suggests a role for MnSOD-generated H2O2 to 
promote the process of differentiation. Future aims will be to incorporate other (i.e. 
genotypically different) neuroblastoma cell lines in these studies to evaluate the 
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responsiveness of a wide range of subtypes to alteration of redox status. Furthermore, a 
more comprehensive survey of 1) other differentiation markers, proliferation, and 
apoptosis, and 2) long-term outcomes on each of these with ROS manipulation will 
improve the clinical impact of these studies. Taken together, our findings suggest that 
retinoid treatment can be tailored to closely regulate ROS and antioxidant expression 
for optimized retinoid therapy. 
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FIGURE 5.2: OVERALL SUMMARY OF THE INFLUENCE OF ROS AND MNSOD ON THE 
DIFFERENTIATION OF SK-N-SH CELLS. 
ATRA generates ROS (O2
• and H2O2) in conjunction with MnSOD upregulation. 
These ROS may act to oxidize ATRA and limit its effectiveness to induce 
differentiation. NAC’s ability to augment ATRA-mediate differentiation could 1) 
prevent this oxidation, or 2) help maintain the nucleus in a reduced state, to thereby 
enhance binding of transcription factors that are essential to promote differentiation. 
Reduction of basal MnSOD activity (small boxes), prior to ATRA-mediated stimulation 
(large box), promoted NF-M expression. Decreased H2O2 production (with MnSOD 
siRNA and PegCAT) (96 hrs) attenuated NF-M, suggesting that this ROS is important 
to promote expression of this differentiation marker. ROS: reactive oxygen species; 
OX: oxidation; NAC: N-acetyl-L-cysteine; MnSOD: manganese superoxide dismutase; 
O2
•: superoxide; H2O2: hydrogen peroxide; PegCAT: polyethylene glycol catalase. 
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